Clinical trials for neurofibromatosis type 1-associated plexiform neurofibromas.
\r\n\t
",isbn:"978-1-83969-084-6",printIsbn:"978-1-83969-083-9",pdfIsbn:"978-1-83969-085-3",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,hash:"521fce75254e23855ed5c3ff4a4f1ea1",bookSignature:"Prof. Xianquan Zhan",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/10220.jpg",keywords:"Sample Preparation, Mass Spectrometry, Metabolite, Metabolome, Nuclear Magnetic Resonance, Lipid Metabolomics, Targeted Metabolomics, Untargeted Metabolomics, Cancer, Neurodegenerative Disease, Endocrine Diseases, Metabolic Disease",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"October 13th 2020",dateEndSecondStepPublish:"November 10th 2020",dateEndThirdStepPublish:"January 9th 2021",dateEndFourthStepPublish:"March 30th 2021",dateEndFifthStepPublish:"May 29th 2021",remainingDaysToSecondStep:"3 months",secondStepPassed:!0,currentStepOfPublishingProcess:4,editedByType:null,kuFlag:!1,biosketch:"A pioneering expert in the field of proteomics and proteofroms, multiomics, biomarkers, and 3P medicine in cancer, appointed as Fellow of Royal Society of Medicine, Fellow and National Representative of EPMA, and Associate Editor of EPMA Journal and BMC Medical Genomics.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"223233",title:"Prof.",name:"Xianquan",middleName:null,surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan",profilePictureURL:"https://mts.intechopen.com/storage/users/223233/images/system/223233.jpg",biography:"Xianquan Zhan received his M.D. and Ph.D. training in preventive medicine at the West China University of Medical Sciences from 1989 to 1999. He received his post-doctoral training in oncology and cancer proteomics at the Central South University and University of Tennessee Health Science Center (UTHSC). He worked at UTHSC and Cleveland Clinic in USA from 2001 to 2012, and achieved the rank of Associate Professor at UTHSC. After that, he became a Full Professor at the Central South University and Shandong First Medical University, and an Advisor of MS/PhD graduate students and postdoctoral fellows. He is also a Fellow of the Royal Society of Medicine, Fellow of EPMA, European EPMA National Representative, full member of the American Society of Clinical Oncology (ASCO), member of the American Association for the Advancement of Sciences (AAAS), Editor-In-Chief of the International Journal of Chronic Diseases & Therapy, Associate Editor of the EPMA Journal and BMC Medical Genomics, and Guest Editor of Frontiers in Endocrinology and Mass Spectrometry Reviews. He has published 135 articles, 23 book chapters and 2 US patents in the field of clinical proteomics and biomarkers. He edited 4 academic books: Proteoforms – Concept and Applications in Medical Sciences, Molecular Network Study of Pituitary Adenomas, and Ubiquitin-Proteasome Pathway. As the Guest editor, he edited 11 special issues in SCI journals such as Mass Spectrometry Reviews, Frontiers in Endocrinology, EPMA Journal, and Med One. His main research interest focuses on the studies of cancer proteomics and proteoforms, multiomics and biomarkers, and the use of modern omics techniques and systems biology for predictive, preventive and personalized medicine (PPPM) and precision medicine (PM) in cancer.",institutionString:"Shandong First Medical University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"2",institution:null}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"6",title:"Biochemistry, Genetics and Molecular Biology",slug:"biochemistry-genetics-and-molecular-biology"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"280415",firstName:"Josip",lastName:"Knapic",middleName:null,title:"Mr.",imageUrl:"https://mts.intechopen.com/storage/users/280415/images/8050_n.jpg",email:"josip@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copy-editing and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"9742",title:"Ubiquitin",subtitle:"Proteasome Pathway",isOpenForSubmission:!1,hash:"af6880d3a5571da1377ac8f6373b9e82",slug:"ubiquitin-proteasome-pathway",bookSignature:"Xianquan Zhan",coverURL:"https://cdn.intechopen.com/books/images_new/9742.jpg",editedByType:"Edited by",editors:[{id:"223233",title:"Prof.",name:"Xianquan",surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9352",title:"Proteoforms",subtitle:"Concept and Applications in Medical Sciences",isOpenForSubmission:!1,hash:"0f0288da2d32c0c0fcda6be0d4d45d67",slug:"proteoforms-concept-and-applications-in-medical-sciences",bookSignature:"Xianquan Zhan",coverURL:"https://cdn.intechopen.com/books/images_new/9352.jpg",editedByType:"Edited by",editors:[{id:"223233",title:"Prof.",name:"Xianquan",surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6694",title:"New Trends in Ion Exchange Studies",subtitle:null,isOpenForSubmission:!1,hash:"3de8c8b090fd8faa7c11ec5b387c486a",slug:"new-trends-in-ion-exchange-studies",bookSignature:"Selcan Karakuş",coverURL:"https://cdn.intechopen.com/books/images_new/6694.jpg",editedByType:"Edited by",editors:[{id:"206110",title:"Dr.",name:"Selcan",surname:"Karakuş",slug:"selcan-karakus",fullName:"Selcan Karakuş"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"6123",title:"Torque Sensors for Robot Joint Control",doi:"10.5772/6614",slug:"torque_sensors_for_robot_joint_control",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/6123.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/6123",previewPdfUrl:"/chapter/pdf-preview/6123",totalDownloads:8061,totalViews:220,totalCrossrefCites:4,totalDimensionsCites:7,hasAltmetrics:0,dateSubmitted:null,dateReviewed:null,datePrePublished:null,datePublished:"December 1st 2008",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/6123",risUrl:"/chapter/ris/6123",book:{slug:"sensors-focus-on-tactile-force-and-stress-sensors"},signatures:"Dzmitry Tsetserukou and Susumu Tachi",authors:null,sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"3374",title:"Sensors",subtitle:"Focus on Tactile Force and Stress Sensors",fullTitle:"Sensors: Focus on Tactile Force and Stress Sensors",slug:"sensors-focus-on-tactile-force-and-stress-sensors",publishedDate:"December 1st 2008",bookSignature:"Jose Gerardo Rocha and Senentxu Lanceros-Mendez",coverURL:"https://cdn.intechopen.com/books/images_new/3374.jpg",licenceType:"CC BY-NC-SA 3.0",editedByType:"Edited by",editors:[{id:"131748",title:"Prof.",name:"Jose",middleName:null,surname:"Gerardo Rocha",slug:"jose-gerardo-rocha",fullName:"Jose Gerardo Rocha"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"6122",title:"How Tactile Sensors Should Be?",slug:"how_tactile_sensors_should_be",totalDownloads:2268,totalCrossrefCites:0,signatures:"Satoshi Saga",authors:[null]},{id:"6123",title:"Torque Sensors for Robot Joint Control",slug:"torque_sensors_for_robot_joint_control",totalDownloads:8061,totalCrossrefCites:4,signatures:"Dzmitry Tsetserukou and Susumu Tachi",authors:[null]},{id:"6124",title:"CMOS Force Sensor with Scanning Signal Process Circuit for Vertical Probe Card",slug:"cmos_force_sensor_with_scanning_signal_process_circuit_for_vertical_probe_card",totalDownloads:3039,totalCrossrefCites:1,signatures:"Jung-Tang Huang, Kuo-Yu Lee and Ming-Chieh Chiu",authors:[null]},{id:"6125",title:"Three-Dimensional Silicon Smart Tactile Imager Using Large Deformation of Swollen Diaphragm with Integrated Piezoresistor Pixel Circuits",slug:"three-dimensional_silicon_smart_tactile_imager_using_large_deformation_of_swollen_diaphragm_with_int",totalDownloads:2216,totalCrossrefCites:0,signatures:"Hidekuni Takao and Makoto Ishida",authors:[null]},{id:"6126",title:"High-Sensitivity and High-Stiffness Force Sensor Using Strain-Deformation Expansion Mechanism",slug:"high-sensitivity_and_high-stiffness_force_sensor_using_strain-deformation_expansion_mechanism",totalDownloads:3032,totalCrossrefCites:0,signatures:"Yong Yu Takashi Chaen and Showzow Tsujio",authors:[null]},{id:"6127",title:"High-Precision Three-Axis Force Sensor for Five-Fingered Haptic Interface",slug:"high-precision_three-axis_force_sensor_for_five-fingered_haptic_interface",totalDownloads:2207,totalCrossrefCites:0,signatures:"Takahiro Endo, Haruhisa Kawasaki, Kazumi Kouketsu and Tetsuya Mouri",authors:[null]},{id:"6128",title:"Optical Three-Axis Tactile Sensor for Robotic Fingers",slug:"optical_three-axis_tactile_sensor_for_robotic_fingers",totalDownloads:2876,totalCrossrefCites:3,signatures:"Masahiro Ohka, Jumpei Takata, Hiroaki Kobayashi, Hirofumi Suzuki, Nobuyuki Morisawa and Hanafiah Bin Yussof",authors:[null]},{id:"6129",title:"Measurement Principles of Optical Three-Axis Tactile Sensor and its Application to Robotic Fingers System",slug:"measurement_principles_of_optical_three-axis_tactile_sensor_and_its_application_to_robotic_fingers_s",totalDownloads:2059,totalCrossrefCites:0,signatures:"Hanafiah Yussof, Jumpei Takata and Masahiro Ohka",authors:[null]},{id:"6130",title:"Three Dimensional Capacitive Force Sensor for Tactile Applications",slug:"three_dimensional_capacitive_force_sensor_for_tactile_applications",totalDownloads:3532,totalCrossrefCites:0,signatures:"Jose Gerardo Rocha and Senentxu Lanceros-Mendez",authors:[null]},{id:"6131",title:"Study on Dynamic Characteristics of Six-Axis Wrist Force/Torque Sensor",slug:"study_on_dynamic_characteristics_of_six-axis_wrist_force_torque_sensor",totalDownloads:2758,totalCrossrefCites:1,signatures:"Ke-Jun Xu",authors:[null]},{id:"6132",title:"Performance Analysis and Optimization of Sizable 6-Axis Force Sensor Based on Stewart Platform",slug:"performance_analysis_and_optimization_of_sizable_6-axis_force_sensor_based_on_stewart_platform",totalDownloads:2295,totalCrossrefCites:0,signatures:"Y. Z. Zhao, T. S. Zhao, L. H. Liu, H. Bian and N. Li",authors:[null]},{id:"6133",title:"Grip Force and Slip Analysis in Robotic Grasp: New Stochastic Paradigm Through Sensor Data Fusion",slug:"grip_force_and_slip_analysis_in_robotic_grasp___new_stochastic_paradigm_through_sensor_data_fusion",totalDownloads:3289,totalCrossrefCites:0,signatures:"Debanik Roy",authors:[null]},{id:"6134",title:"Development of Anthropomorphic Robot Hand with Tactile Sensor:SKKU Hand II",slug:"development_of_anthropomorphic_robot_hand_with_tactile_sensor_skku_hand_ii",totalDownloads:2608,totalCrossrefCites:0,signatures:"Byung June Choi, Jooyoung Chun and and Hyouk Ryeol Choi",authors:[null]},{id:"6135",title:"Design of a Tactile Sensor for Robot Hands",slug:"design_of_a_tactile_sensor_for_robot_hands",totalDownloads:3618,totalCrossrefCites:4,signatures:"Giorgio Cannata and Marco Maggiali",authors:[null]},{id:"6136",title:"Tactile Sensing for Robotic Applications",slug:"tactile_sensing_for_robotic_applications",totalDownloads:8178,totalCrossrefCites:3,signatures:"Ravinder S. Dahiya and Maurizio Valle",authors:[null]},{id:"6137",title:"Fast and Accurate Tactile Sensor System for a Human-Interactive Robot",slug:"fast_and_accurate_tactile_sensor_system_for_a_human-interactive_robot",totalDownloads:2090,totalCrossrefCites:8,signatures:"Toshiharu Mukai, Shinya Hirano and Yo Kato",authors:[null]},{id:"6138",title:"Development of a Humanoid with Distributed Multi-Axis Deformation Sense with Full-Body Soft Plastic Foam Cover as Flesh of a Robot",slug:"development_of_a_humanoid_with_distributed_multi-axis_deformation_sense_with_full-body_soft_plastic_",totalDownloads:2005,totalCrossrefCites:4,signatures:"Marika Hayashi, Tomoaki Yoshikai and Masayuki Inaba",authors:[null]},{id:"6139",title:"Research and Preparation Method of Flexible Tactile Sensor Material",slug:"research_and_preparation_method_of_flexible_tactile_sensor_material",totalDownloads:2881,totalCrossrefCites:2,signatures:"Ying Huang, Min Wang, Huaili Qiu, Bei Xiang and Yugang Zhang",authors:[null]},{id:"6140",title:"A Principle and Characteristics of a Flexible and Stretchable Tactile Sensor Based on Static Electricity",slug:"a_principle_and_characteristics_of_a_flexible_and_stretchable_tactile_sensor_based_on_static_electri",totalDownloads:2245,totalCrossrefCites:0,signatures:"Yasunori Tada, Masahiro Inoue, Toshimi Kawasaki, Yasushi Kawahito, Hiroshi Ishiguro and Katsuaki Suganuma",authors:[{id:"11981",title:"Prof.",name:"Hiroshi",middleName:null,surname:"Ishiguro",fullName:"Hiroshi Ishiguro",slug:"hiroshi-ishiguro"}]},{id:"6141",title:'Design Considerations for Multimodal "Sensitive Skins" for Robotic Companions',slug:"design_considerations_for_multimodal_sensitive_skins_for_robotic_companions",totalDownloads:2039,totalCrossrefCites:0,signatures:"Walter Dan Stiehl",authors:[null]},{id:"6142",title:"Compliant Tactile Sensors for High-Aspect-Ratio Form Metrology",slug:"compliant_tactile_sensors_for_high-aspect-ratio_form_metrology",totalDownloads:1987,totalCrossrefCites:3,signatures:"Erwin Peiner",authors:[null]},{id:"6143",title:"Tactile Sensor Without Wire and Sensing Element in the Tactile Region Using New Rubber Material",slug:"tactile_sensor_without_wire_and_sensing_element_in_the_tactile_region_using_new_rubber_material",totalDownloads:2337,totalCrossrefCites:7,signatures:"Yo Kato and Toshiharu Mukai",authors:[null]},{id:"6144",title:"Recognition of Contact State of Four Layers Arrayed Type Tactile Sensor by Using Neural Networks",slug:"recognition_of_contact_state_of_four_layers_arrayed_type_tactile_sensor_by_using_neural_networks",totalDownloads:1639,totalCrossrefCites:0,signatures:"Seiji Aoyagi",authors:[null]},{id:"6145",title:"Tactile Information Processing for the Orientation Behaviour of Sand Scorpions",slug:"tactile_information_processing_for_the_orientation_behaviour_of_sand_scorpions",totalDownloads:1976,totalCrossrefCites:1,signatures:"DaeEun Kim",authors:[null]}]},relatedBooks:[{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"36273",title:"Introduction to Infrared Spectroscopy",slug:"introduction-to-infrared-spectroscopy",signatures:"Theophile Theophanides",authors:[{id:"37194",title:"Dr.",name:"Theophanides",middleName:null,surname:"Theophile",fullName:"Theophanides Theophile",slug:"theophanides-theophile"}]},{id:"36166",title:"Using Infrared Spectroscopy to Identify New Amorphous Phases - A Case Study of Carbonato Complex Formed by Mechanochemical Processing",slug:"using-infrared-spectroscopy-to-identify-new-amorphous-phases-a-case-study-of-carbonato-complexes-fo",signatures:"Tadej Rojac, Primož Šegedin and Marija Kosec",authors:[{id:"25116",title:"Prof.",name:"Marija",middleName:null,surname:"Kosec",fullName:"Marija Kosec",slug:"marija-kosec"},{id:"105876",title:"Dr.",name:"Tadej",middleName:null,surname:"Rojac",fullName:"Tadej Rojac",slug:"tadej-rojac"},{id:"111754",title:"Prof.",name:"Primoz",middleName:null,surname:"Segedin",fullName:"Primoz Segedin",slug:"primoz-segedin"}]},{id:"36167",title:"Application of Infrared Spectroscopy to Analysis of Chitosan/Clay Nanocomposites",slug:"application-of-infrared-spectroscopy-to-analysis-of-chitosan-clay-nanocomposites",signatures:"Suédina M.L. Silva, Carla R.C. Braga, Marcus V.L. Fook, Claudia M.O. Raposo, Laura H. Carvalho and Eduardo L. Canedo",authors:[{id:"104808",title:"Prof.",name:"Suedina Maria",middleName:"De Lima",surname:"Silva",fullName:"Suedina Maria Silva",slug:"suedina-maria-silva"},{id:"111910",title:"Prof.",name:"Carla",middleName:"Lima",surname:"R. C. Braga",fullName:"Carla R. C. Braga",slug:"carla-r.-c.-braga"},{id:"142933",title:"Prof.",name:"Marcus Vinícius",middleName:null,surname:"Lia Fook",fullName:"Marcus Vinícius Lia Fook",slug:"marcus-vinicius-lia-fook"},{id:"142934",title:"Prof.",name:"Claudia Maria",middleName:null,surname:"De Oliveira Raposo",fullName:"Claudia Maria De Oliveira Raposo",slug:"claudia-maria-de-oliveira-raposo"},{id:"142936",title:"Prof.",name:"Laura",middleName:null,surname:"Hecker De Carvalho",fullName:"Laura Hecker De Carvalho",slug:"laura-hecker-de-carvalho"},{id:"142939",title:"Dr.",name:"Eduardo Luis",middleName:null,surname:"Canedo",fullName:"Eduardo Luis Canedo",slug:"eduardo-luis-canedo"}]},{id:"36168",title:"Structural and Optical Behavior of Vanadate-Tellurate Glasses Containing PbO or Sm2O3",slug:"structural-and-optical-behavior-of-vanadate-tellurate-glasses",signatures:"E. Culea, S. Rada, M. Culea and M. Rada",authors:[{id:"114650",title:"Dr",name:"Eugen",middleName:null,surname:"Culea",fullName:"Eugen Culea",slug:"eugen-culea"},{id:"114653",title:"Dr.",name:"Simona",middleName:null,surname:"Rada",fullName:"Simona Rada",slug:"simona-rada"}]},{id:"36169",title:"Water in Rocks and Minerals - Species, Distributions, and Temperature Dependences",slug:"water-in-rocks-and-minerals-species-distributions-and-temperature-dependences",signatures:"Jun-ichi Fukuda",authors:[{id:"105384",title:"Dr.",name:"Jun-Ichi",middleName:null,surname:"Fukuda",fullName:"Jun-Ichi Fukuda",slug:"jun-ichi-fukuda"}]},{id:"36170",title:"Attenuated Total Reflection - Infrared Spectroscopy Applied to the Study of Mineral - Aqueous Electrolyte Solution Interfaces: A General Overview and a Case Study",slug:"attenuated-total-reflection-infrared-spectroscopy-applied-to-the-study-of-mineral-aqueous-el",signatures:"Grégory Lefèvre, Tajana Preočanin and Johannes Lützenkirchen",authors:[{id:"108416",title:"Dr.",name:"Johannes",middleName:null,surname:"Lützenkirchen",fullName:"Johannes Lützenkirchen",slug:"johannes-lutzenkirchen"},{id:"111675",title:"Dr.",name:"Gregory",middleName:null,surname:"Lefevre",fullName:"Gregory Lefevre",slug:"gregory-lefevre"},{id:"111676",title:"Prof.",name:"Tajana",middleName:null,surname:"Preocanin",fullName:"Tajana Preocanin",slug:"tajana-preocanin"}]},{id:"36171",title:"Research of Calcium Phosphates Using Fourier Transform Infrared Spectroscopy",slug:"research-of-calcium-phosphates-using-fourier-transformation-infrared-spectroscopy",signatures:"Liga Berzina-Cimdina and Natalija Borodajenko",authors:[{id:"110522",title:"Prof.",name:"Liga",middleName:null,surname:"Berzina-Cimdina",fullName:"Liga Berzina-Cimdina",slug:"liga-berzina-cimdina"},{id:"112181",title:"MSc.",name:"Natalija",middleName:null,surname:"Borodajenko",fullName:"Natalija Borodajenko",slug:"natalija-borodajenko"}]},{id:"36172",title:"FTIR Spectroscopy of Adsorbed Probe Molecules for Analyzing the Surface Properties of Supported Pt (Pd) Catalysts",slug:"ftir-spectroscopy-of-adsorbed-probe-molecules-for-analyzing-the-surface-properties-of-supported-pt-p",signatures:"Olga B. Belskaya, Irina G. Danilova, Maxim O. Kazakov, Roman M. Mironenko, Alexander V. Lavrenov and Vladimir A. Likholobov",authors:[{id:"107715",title:"Dr.",name:"Olga",middleName:null,surname:"Belskaya",fullName:"Olga Belskaya",slug:"olga-belskaya"},{id:"140198",title:"Dr.",name:"Irina",middleName:null,surname:"Danilova",fullName:"Irina Danilova",slug:"irina-danilova"},{id:"140200",title:"Dr.",name:"Maxim",middleName:null,surname:"Kazakov",fullName:"Maxim Kazakov",slug:"maxim-kazakov"},{id:"140202",title:"Mr.",name:"Roman",middleName:"Mikhailovich",surname:"Mironenko",fullName:"Roman Mironenko",slug:"roman-mironenko"},{id:"140203",title:"Dr.",name:"Alexander",middleName:null,surname:"Lavrenov",fullName:"Alexander Lavrenov",slug:"alexander-lavrenov"},{id:"140204",title:"Prof.",name:"Vladimir",middleName:null,surname:"Likholobov",fullName:"Vladimir Likholobov",slug:"vladimir-likholobov"}]},{id:"36173",title:"Hydrothermal Treatment of Hokkaido Peat - An Application of FTIR and 13C NMR Spectroscopy on Examining of Artificial Coalification Process and Development",slug:"hydrothermal-treatment-of-hokkaido-peat-an-application-of-ftir-and-13c-nmr-spectroscopy-on-examinin",signatures:"Anggoro Tri Mursito and Tsuyoshi Hirajima",authors:[{id:"104786",title:"Dr.",name:"Anggoro Tri",middleName:null,surname:"Mursito",fullName:"Anggoro Tri Mursito",slug:"anggoro-tri-mursito"},{id:"110978",title:"Prof.",name:"Tsuyoshi",middleName:null,surname:"Hirajima",fullName:"Tsuyoshi Hirajima",slug:"tsuyoshi-hirajima"}]},{id:"36174",title:"FTIR - An Essential Characterization Technique for Polymeric Materials",slug:"ftir-an-essential-characterization-technique-for-polymeric-materials",signatures:"Vladimir A. Escobar Barrios, José R. Rangel Méndez, Nancy V. Pérez Aguilar, Guillermo Andrade Espinosa and José L. Dávila Rodríguez",authors:[{id:"12709",title:"Dr.",name:"Jose Rene",middleName:null,surname:"Rangel-Mendez",fullName:"Jose Rene Rangel-Mendez",slug:"jose-rene-rangel-mendez"},{id:"12711",title:"Dr.",name:"Vladimir Alonso",middleName:null,surname:"Escobar Barrios",fullName:"Vladimir Alonso Escobar Barrios",slug:"vladimir-alonso-escobar-barrios"},{id:"112164",title:"Dr",name:"Guillermo",middleName:null,surname:"Andrade-Espinosa",fullName:"Guillermo Andrade-Espinosa",slug:"guillermo-andrade-espinosa"},{id:"112165",title:"Dr.",name:"José Luis",middleName:null,surname:"Dávila-Rodríguez",fullName:"José Luis Dávila-Rodríguez",slug:"jose-luis-davila-rodriguez"},{id:"112167",title:"Dr.",name:"Nancy Verónica",middleName:null,surname:"Pérez-Aguilar",fullName:"Nancy Verónica Pérez-Aguilar",slug:"nancy-veronica-perez-aguilar"}]},{id:"36175",title:"Preparation and Characterization of PVDF/PMMA/Graphene Polymer Blend Nanocomposites by Using ATR-FTIR Technique",slug:"preparation-and-characterization-of-pvdf-pmma-graphene-polymer-blend-nanocomposites-by-using-ft-ir-t",signatures:"Somayeh Mohamadi",authors:[{id:"108556",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohamadi",fullName:"Somayeh Mohamadi",slug:"somayeh-mohamadi"}]},{id:"36176",title:"Reflectance IR Spectroscopy",slug:"fundamental-of-reflectance-ir-spectroscopy",signatures:"Zahra Monsef Khoshhesab",authors:[{id:"111629",title:"Dr.",name:"Zahra",middleName:null,surname:"Monsef Khoshhesab",fullName:"Zahra Monsef Khoshhesab",slug:"zahra-monsef-khoshhesab"}]},{id:"36177",title:"Evaluation of Graft Copolymerization of Acrylic Monomers Onto Natural Polymers by Means Infrared Spectroscopy",slug:"evaluation-of-graft-copolymerization-of-acrylic-monomers-onto-natural-polymers-by-means-infrared-spe",signatures:"José Luis Rivera-Armenta, Cynthia Graciela Flores-Hernández, Ruth Zurisadai Del Angel-Aldana, Ana María Mendoza-Martínez, Carlos Velasco-Santos and Ana Laura Martínez-Hernández",authors:[{id:"37761",title:"Prof.",name:"Ana Laura",middleName:null,surname:"Martinez-Hernandez",fullName:"Ana Laura Martinez-Hernandez",slug:"ana-laura-martinez-hernandez"},{id:"107855",title:"Dr.",name:"Jose Luis",middleName:null,surname:"Rivera Armenta",fullName:"Jose Luis Rivera Armenta",slug:"jose-luis-rivera-armenta"},{id:"108894",title:"MSc.",name:"Cynthia Graciela",middleName:null,surname:"Flores-Hernández",fullName:"Cynthia Graciela Flores-Hernández",slug:"cynthia-graciela-flores-hernandez"},{id:"108896",title:"MSc.",name:"Ruth Zurisadai",middleName:null,surname:"Del Angel Aldana",fullName:"Ruth Zurisadai Del Angel Aldana",slug:"ruth-zurisadai-del-angel-aldana"},{id:"108898",title:"Dr.",name:"Carlos",middleName:null,surname:"Velasco-Santos",fullName:"Carlos Velasco-Santos",slug:"carlos-velasco-santos"},{id:"108905",title:"Dr.",name:"Ana Maria",middleName:null,surname:"Mendoza-Martínez",fullName:"Ana Maria Mendoza-Martínez",slug:"ana-maria-mendoza-martinez"}]},{id:"36178",title:"Applications of FTIR on Epoxy Resins - Identification, Monitoring the Curing Process, Phase Separation and Water Uptake",slug:"applications-of-ftir-on-epoxy-resins-identification-monitoring-the-curing-process-phase-separatio",signatures:"María González González, Juan Carlos Cabanelas and Juan Baselga",authors:[{id:"107857",title:"Prof.",name:"Juan",middleName:null,surname:"Baselga",fullName:"Juan Baselga",slug:"juan-baselga"},{id:"138113",title:"Dr.",name:"María",middleName:null,surname:"González",fullName:"María González",slug:"maria-gonzalez"},{id:"138114",title:"Dr.",name:"Juan C.",middleName:null,surname:"Cabanelas",fullName:"Juan C. Cabanelas",slug:"juan-c.-cabanelas"}]},{id:"36179",title:"Use of FTIR Analysis to Control the Self-Healing Functionality of Epoxy Resins",slug:"use-of-ft-ir-analysis-to-control-the-self-healing-functionality-of-epoxy-resins",signatures:"Liberata Guadagno and Marialuigia Raimondo",authors:[{id:"106836",title:"Prof.",name:"Liberata",middleName:null,surname:"Guadagno",fullName:"Liberata Guadagno",slug:"liberata-guadagno"}]},{id:"36180",title:"Infrared Analysis of Electrostatic Layer-By-Layer Polymer Membranes Having Characteristics of Heavy Metal Ion Desalination",slug:"infrared-analysis-of-electrostatic-layer-by-layer-polymer-membranes-having-characteristics-of-heavy",signatures:"Weimin Zhou, Huitan Fu and Takaomi Kobayashi",authors:[{id:"110384",title:"Dr.",name:"Takaomi",middleName:null,surname:"Kobayashi",fullName:"Takaomi Kobayashi",slug:"takaomi-kobayashi"}]},{id:"36181",title:"Infrared Spectroscopy as a Tool to Monitor Radiation Curing",slug:"infrared-spectroscopy-as-a-tool-to-monitor-radiation-curing",signatures:"Marco Sangermano, Patrick Meier and Spiros Tzavalas",authors:[{id:"112286",title:"Dr.",name:"Spiros",middleName:null,surname:"Tzavalas",fullName:"Spiros Tzavalas",slug:"spiros-tzavalas"},{id:"114382",title:"Prof.",name:"Marco",middleName:null,surname:"Sangermano",fullName:"Marco Sangermano",slug:"marco-sangermano"},{id:"114384",title:"Dr",name:"Patrick",middleName:null,surname:"Meier",fullName:"Patrick Meier",slug:"patrick-meier"}]},{id:"36182",title:"Characterization of Compositional Gradient Structure of Polymeric Materials by FTIR Technology",slug:"characterization-of-compositional-gradient-structure-of-polymeric-materials-by-ft-ir-technology",signatures:"Alata Hexig and Bayar Hexig",authors:[{id:"20867",title:"Dr.",name:"Bayar",middleName:null,surname:"Hexig",fullName:"Bayar Hexig",slug:"bayar-hexig"},{id:"111986",title:"Dr.",name:"Alata",middleName:null,surname:"Hexig",fullName:"Alata Hexig",slug:"alata-hexig"}]},{id:"36183",title:"Fourier Transform Infrared Spectroscopy - Useful Analytical Tool for Non-Destructive Analysis",slug:"fourier-trasform-infrared-spectroscopy-useful-analytical-tool-for-non-destructive-analysis",signatures:"Simona-Carmen Litescu, Eugenia D. Teodor, Georgiana-Ileana Truica, Andreia Tache and Gabriel-Lucian Radu",authors:[{id:"24425",title:"Dr.",name:"Simona Carmen",middleName:null,surname:"Litescu",fullName:"Simona Carmen Litescu",slug:"simona-carmen-litescu"},{id:"24429",title:"Prof.",name:"Gabriel-Lucian",middleName:null,surname:"Radu",fullName:"Gabriel-Lucian Radu",slug:"gabriel-lucian-radu"},{id:"108318",title:"Dr.",name:"Eugenia D.",middleName:null,surname:"Teodor",fullName:"Eugenia D. Teodor",slug:"eugenia-d.-teodor"},{id:"108323",title:"Dr.",name:"Georgiana-Ileana",middleName:null,surname:"Badea",fullName:"Georgiana-Ileana Badea",slug:"georgiana-ileana-badea"},{id:"136337",title:"Ms.",name:"Andreia",middleName:null,surname:"Tache",fullName:"Andreia Tache",slug:"andreia-tache"}]},{id:"36184",title:"Infrared Spectroscopy in the Analysis of Building and Construction Materials",slug:"infrared-spectroscopy-of-cementitious-materials",signatures:"Lucia Fernández-Carrasco, D. Torrens-Martín, L.M. Morales and Sagrario Martínez-Ramírez",authors:[{id:"107401",title:"Dr.",name:"Lucia J",middleName:null,surname:"Fernández",fullName:"Lucia J Fernández",slug:"lucia-j-fernandez"}]},{id:"36185",title:"Infrared Spectroscopy Techniques in the Characterization of SOFC Functional Ceramics",slug:"infrared-spectroscopy-techniques-in-the-characterization-of-sofc-functional-ceramics",signatures:"Daniel A. Macedo, Moisés R. Cesário, Graziele L. Souza, Beatriz Cela, Carlos A. Paskocimas, Antonio E. Martinelli, Dulce M. A. Melo and Rubens M. Nascimento",authors:[{id:"102015",title:"MSc.",name:"Daniel",middleName:null,surname:"Macedo",fullName:"Daniel Macedo",slug:"daniel-macedo"},{id:"112309",title:"MSc",name:"Moisés",middleName:"Romolos",surname:"Cesário",fullName:"Moisés Cesário",slug:"moises-cesario"},{id:"112310",title:"Ms.",name:"Graziele",middleName:null,surname:"Souza",fullName:"Graziele Souza",slug:"graziele-souza"},{id:"112311",title:"MSc.",name:"Beatriz",middleName:null,surname:"Cela",fullName:"Beatriz Cela",slug:"beatriz-cela"},{id:"112312",title:"Prof.",name:"Carlos",middleName:null,surname:"Paskocimas",fullName:"Carlos Paskocimas",slug:"carlos-paskocimas"},{id:"112314",title:"Prof.",name:"Antonio",middleName:null,surname:"Martinelli",fullName:"Antonio Martinelli",slug:"antonio-martinelli"},{id:"112315",title:"Prof.",name:"Dulce",middleName:null,surname:"Melo",fullName:"Dulce Melo",slug:"dulce-melo"},{id:"112316",title:"Dr.",name:"Rubens",middleName:"Maribondo Do",surname:"Nascimento",fullName:"Rubens Nascimento",slug:"rubens-nascimento"}]},{id:"36186",title:"Infrared Spectroscopy of Functionalized Magnetic Nanoparticles",slug:"infrared-spectroscopy-of-functionalized-magnetic-nanoparticles",signatures:"Perla E. García Casillas, Claudia A. Rodriguez Gonzalez and Carlos A. Martínez Pérez",authors:[{id:"104636",title:"Dr.",name:"Perla E.",middleName:null,surname:"García Casillas",fullName:"Perla E. García Casillas",slug:"perla-e.-garcia-casillas"},{id:"112440",title:"Dr.",name:"Carlos A.",middleName:null,surname:"Martínez Pérez",fullName:"Carlos A. Martínez Pérez",slug:"carlos-a.-martinez-perez"},{id:"112441",title:"Dr.",name:"Claudia A.",middleName:null,surname:"Rodriguez Gonzalez",fullName:"Claudia A. Rodriguez Gonzalez",slug:"claudia-a.-rodriguez-gonzalez"}]},{id:"36187",title:"Determination of Adsorption Characteristics of Volatile Organic Compounds Using Gas Phase FTIR Spectroscopy Flow Analysis",slug:"determination-of-adsorption-characteristics-of-volatile-organic-compounds-using-gas-phase-ftir-spect",signatures:"Tarik Chafik",authors:[{id:"107310",title:"Prof.",name:"Tarik",middleName:null,surname:"Chafik",fullName:"Tarik Chafik",slug:"tarik-chafik"}]},{id:"36188",title:"Identification of Rocket Motor Characteristics from Infrared Emission Spectra",slug:"identification-of-rocket-motor-characteristics-from-infrared-emission-spectra",signatures:"N. Hamp, J.H. Knoetze, C. Aldrich and C. Marais",authors:[{id:"112229",title:"Prof.",name:"Chris",middleName:null,surname:"Aldrich",fullName:"Chris Aldrich",slug:"chris-aldrich"},{id:"112232",title:"Prof.",name:"Hansie",middleName:null,surname:"Knoetze",fullName:"Hansie Knoetze",slug:"hansie-knoetze"},{id:"135327",title:"Ms.",name:"Corne",middleName:null,surname:"Marais",fullName:"Corne Marais",slug:"corne-marais"}]},{id:"36189",title:"Optical Technologies for Determination of Pesticide Residue",slug:"optical-technology-for-determination-of-pesticide-residue",signatures:"Yankun Peng, Yongyu Li and Jingjing Chen",authors:[{id:"113343",title:"Prof.",name:"Yankun",middleName:null,surname:"Peng",fullName:"Yankun Peng",slug:"yankun-peng"},{id:"116636",title:"Dr.",name:"Yongyu",middleName:null,surname:"Li",fullName:"Yongyu Li",slug:"yongyu-li"},{id:"116637",title:"Dr.",name:"Jingjing",middleName:null,surname:"Chen",fullName:"Jingjing Chen",slug:"jingjing-chen"}]},{id:"36190",title:"High Resolution Far Infrared Spectra of the Semiconductor Alloys Obtained Using the Synchrotron Radiation as Source",slug:"high-resolution-spectra-of-semiconductor-s-alloys-obtained-using-the-far-infrared-synchrotron-radi",signatures:"E.M. Sheregii",authors:[{id:"102655",title:"Prof.",name:"Eugen",middleName:null,surname:"Sheregii",fullName:"Eugen Sheregii",slug:"eugen-sheregii"}]},{id:"36191",title:"Effective Reaction Monitoring of Intermediates by ATR-IR Spectroscopy Utilizing Fibre Optic Probes",slug:"effective-reaction-monitoring-of-intermediates-by-atr-ir-spectroscopy-utilizing-fibre-optic-probes",signatures:"Daniel Lumpi and Christian Braunshier",authors:[{id:"109019",title:"Dr.",name:"Christian",middleName:null,surname:"Braunshier",fullName:"Christian Braunshier",slug:"christian-braunshier"},{id:"111798",title:"MSc.",name:"Daniel",middleName:null,surname:"Lumpi",fullName:"Daniel Lumpi",slug:"daniel-lumpi"}]}]}]},onlineFirst:{chapter:{type:"chapter",id:"68902",title:"Therapeutic Development in Neurofibromatosis",doi:"10.5772/intechopen.89037",slug:"therapeutic-development-in-neurofibromatosis",body:'\nThe neurofibromatoses are a heterogenous group of familial tumor predisposition syndromes that result from pathogenic variants in tumor suppressor genes leading to dysregulation in various cellular pathways. This dysregulation eventually leads to tumors of the central and peripheral nervous systems as well as multiorgan involvement. The incidence of Neurofibromatosis type 1 (NF1) is approximately 1 in every 2500–3500 births [1], while the incidence of neurofibromatosis type 2 (NF2) is approximately 1 in every 25,000–33,000 births [2]. Schwannomatosis (SWN) has been identified as a distinct entity with different genetic etiology and clinical phenotype from NF2, but it is difficult to assess the precise incidence of this condition. Although the tumors that develop most frequently in NF1, NF2 and SWN are histologically benign, they can cause significant neurologic disabilities and even mortality due to the involvement of the central and peripheral nervous systems. These tumors represent a unique therapeutic challenge due to the heterogeneity in severity and rate of progression among patients and hence novel therapeutic approaches are needed. In this chapter, we will review the recent studies in the field of neurofibromatosis therapeutics along with the collaborative efforts for innovative clinical trial designs.
\nThe establishment of the NFCTC in 2006 by the Department of Defense was a landmark in the field of NF therapeutics development [3]. The consortium has been in continuous operation since inception. It provides infrastructure, and shared resources across multiple institutions to generate resource-efficient clinical trials. The REiNS working groups are another clear example of the influence of collaboration among NF experts to advance the NF drug development efforts. The Children’s Tumor Foundation (CTF) has provided support to the NF community, including efforts to advance research as well as public education and patient support. In 2007, the CTF invested $4 million to launch the Neurofibromatosis Preclinical Consortium (NFPC) to test candidate drug therapies in NF1 and NF2 models. The Neurofibromatosis Therapeutic Acceleration (NTAP) was established as a private philanthropy to accelerate the development of effective therapeutics for pNFs and cNFs. NTAP has partnered with CTF in the evaluation of potential therapeutic agents in animal models of pNFs.
\nThe collaborative efforts among academic, federal regulatory, and private foundations have resulted in early successes in the NF therapeutic development. In February 2018, selumetinib, a MEK1/2 inhibitor co-developed by AstraZenca and Merck&Co, received breakthrough status from the FDA. Selumetinib was granted Orphan Drug Designation based on data from the phase II trial that tested selumetinib in pediatric patients with inoperable pNFs (NCT01362803) [4] and hence, selumetinib may become the first approved drug for NF. This success highlights the power of collaboration, which moved Selumetinib from a repurposed oncology drug to its current clinical success in NF patients. The funders involved for in this “MEK story” are the CTF, the National Institute of Health (NIH), the Congressionally Directed Medical Research Program (CDMRP) through NFCTC, and the NTAP at Johns Hopkins University [5].
\nUnderstanding of the pathogenesis and molecular landscape of the NF1-associated tumors has advanced dramatically in recent years. This advancement, along with the continued collaborative approaches across the research community, has fueled therapeutic development efforts against many of the NF1 manifestations. Therapeutic development in NF1 has been tumor-specific, due to the substantial heterogeneity of the development and behavior of NF1-associated tumors across and within patients. Plexiform neurofibromas (pNFs), the source of major morbidity in NF1, has been an area of major focus for therapeutic development, followed by other NF1-associated tumors including cutaneous neurofibromas (cNF), optic pathway gliomas (OPG), and malignant peripheral nerve sheath tumors (MPNST).
\nPlexiform neurofibromas (pNFs) affect up to 50% of NF1 patients and can involve any peripheral nerve [6, 7]. They occur most commonly in the trunk, followed by the extremities [6]. pNFs tend to grow most rapidly in early childhood and may increase by ≥20% per volume per year in young children [8]. Though surgery remains the mainstay for treatment of pNF, complete resection is virtually impossible due to the frequent involvement of adjacent normal tissue, and occasionally critical structures. Moreover, surgical resection is frequently challenging since pNF can cross tissue planes and involve multiple body regions. The most common morbidities leading to surgery are neurologic, disfigurement, and airway involvement [9]. A substantial risk of pNF regrowth after surgical resection has motivated the ongoing research to find non-invasive therapies for pNF.
\nThere are multiple ongoing clinical trials (Table 1) targeting pNF which represent a rapid expansion in the pNF therapeutic landscape. Though some of the tested drugs have failed to achieve the primary endpoint, they helped establish the natural history of the growth rates of pNF [10, 11]. The therapeutic development efforts in pNFs had shifted from testing “empirically,” usually cytotoxic, agents to agents being supported by well-established transitional studies. The first agent that showed radiographic response was imatinib, with a response rate of 17% [12]. Ras-pathway targeted therapy has been of particular interest, as it provides an opportunity for treating multiple manifestations of NF1 with one drug. For example, Selumetinib, which is a MEK (mitogen-activated protein kinase) inhibitor, has shown activity in pNF and low-grade gliomas (including OPG) associated with NF1 [13].
\nDrug | \nTarget | \nPhase | \nAge (y) | \nEndpoints | \nResults | \n
---|---|---|---|---|---|
Thalidomide [14] | \nAngiogenesis | \nI | \n>5 | \nORR | \nCompleted/unclear benefit | \n
Sirolimus [15] NCT00634270 | \nmTOR | \nII | \n>3 | \n3D ORR, TTP | \nModest increase in TTP, no objective response | \n
Sorafenib [16] NCT00727233 | \nRaf kinase, c-kit, PDGF, VEGFR2,3 | \nI | \n3–18 | \n3D ORR | \nIntolerable, decrease in QOL due to pain, no objective response | \n
Pirfenidone [17, 18] NCT00076102 | \nFibroblast proliferation | \nI, II | \n3–21 | \n3D ORR | \nCompleted, no objective response | \n
Cediranib NCT00326872 | \nVEGFR-1, -2, -3 | \nII | \n≥18 | \n3D ORR | \nTerminated due to slow accrual | \n
Tipifarnib [19] NCT00021541 | \nFarnesyl transferase | \nI, II | \n3–25 | \nTTP, 3D ORR | \nCompleted, No difference in TTP | \n
PEG-Interferon alpha 2b [20, 21] NCT00396019 | \nImmune, angiogenesis | \nI, II | \n18 months–21 years in phase II | \nTTP, 3D ORR | \nDoubled TTP, 3D ORR less than 20% | \n
Vinblastine/Methotrexate NCT00030264 | \nCytotoxic | \nII | \n≤25 | \nTTP | \nCompleted, pending results | \n
Celecoxib; PEG-Interferon alpha 2b NCT00846430 | \nImmune, angiogenesis | \nII | \n2–30 | \nSymptoms improvement, ORR | \nActive, not recruiting | \n
Nilotinib NCT01275586 | \nBCR-ABL, PDGFR, c-kit | \nPilot | \n≥18 | \nRECIST,3D ORR | \nCompleted | \n
Everolimus [22] NCT01412892 | \nmTOR | \nII | \n18–60 | \n3D ORR | \nCompleted, no objective response | \n
Everolimus NCT01365468 | \nmTOR | \nII | \n>10 | \n3D ORR, TTP | \nTerminated due to slow accrual | \n
Imatinib [23] NCT01673009 | \nc-kit, PDGFR | \nII | \n3–65 | \nRECIST, 3D ORR | \n17% 3D ORR | \n
Sunitinib NCT01402817 | \nPDGFR, VEGFR, c-kit | \nII | \n3–65 | \n3D ORR | \nTerminated (1 patient died) | \n
Pexidartinib [24] NCT02390752 | \nc-kit, FLT3, CSF1R | \nI, II | \n3–31 | \nORR | \nRecruiting | \n
Cabozantinib NCT02101736 | \nRET, c-MET, VEGFR | \nII | \n≥3 | \n3D ORR | \nRecruiting | \n
Trametinib NCT02124772 | \nMEK | \nI | \n1 month–17 years | \nPK, PD, toxicity | \nRecruiting | \n
PD-0325901 [25] NCT02096471 | \nMEK | \nII | \n≥16 | \n3D ORR | \nCompleted, 42% 3D ORR | \n
Selumetinib [26] NCT01362803 | \nMEK | \nI, II | \n2–18 | \n3D ORR | \nActive, not recruiting, 71% 3D ORR | \n
Selumetinib NCT02407405 | \nMEK | \nII | \n≥18 | \n3D ORR | \nRecruiting | \n
Binimetinib NCT03231306 | \nMEK | \nII | \n≥1 | \n3D ORR | \nRecruiting | \n
Selumetinib (intermittent dosing) NCT03326388 | \nMEK | \nI, II | \n3–18 | \nToxicity, 3D ORR | \nActive, not recruiting | \n
Trametinib NCT03363217 | \nMEK | \nII | \n1 month–25 years | \n3D ORR, TTP RECIST | \nRecruiting | \n
Imatinib (in pNF with airway involvement) NCT03688568 | \nc-kit, PDGFR | \nII | \n6 months–12 years | \nSleep study/PFT, 3D ORR | \nRecruiting | \n
Clinical trials for neurofibromatosis type 1-associated plexiform neurofibromas.
\nAbbreviations: 3D ORR, volumetric objective radiographic response; BCR-ABL, fusion gene of breakpoint cluster region and Abl1; c-kit, kit ligand or stem cell factor; c-MET, MET proton-oncogene; CSF1R, colony stimulating factor 1 receptor; FLT3, Fms-like tyrosine kinase 11; MEK, mitogen activated protein kinas; mTOR, mammalian target of rapamycin; PD, pharmacodynamic; PDGFR platelet-derived growth factor; PFT, pulmonary function test; PK, pharmacokinetics; RECIST, Response Evaluation Criteria In Solid Tumors; RET, rearranged during transfection proto-oncogene; TTP, time to progression; VEGFR vascular endothelial growth factor receptor; ORR, objective response rate.
Optic pathway glioma (OPG) is the most common form of glioma seen in individuals with NF1. While 15–20% of children with NF1 will develop OPG [27, 28] only 30–50% will be symptomatic and one-third will require therapeutic intervention [29]. In those with confirmed decline in visual acuity (VA) or involvement in the hypothalamus, chemotherapy is the mainstay of treatment. First-line chemotherapeutic agents include vincristine and carboplatin [30], while second-line agents include vinblastine [31], vinorelbine [32], and temozolomide [33]. There is a report of four cases of refractory OPG (two sporadic and two NF1-associated OPG) that showed marked improvement in VA following treatment with bevacizumab [34]. These agents rarely restore the premorbid visual acuity and the aim of treatment is usually to stabilize disease and prevent further worsening [35, 36]. Radiotherapy is usually avoided in NF1-associated OPG for concern of secondary tumors [37] and moya moya syndrome [38] Surgical excision of OPG is not feasible due to the tumor location and is usually reserved for instances of complete loss of vision, severe proptosis, or hydrocephalus.
\nRecently, small molecule inhibitors have been used for refractory OPG in clinical trials (Table 2). Among these agents, selumetinib has shown promising results in phase II studies and was proven to be active in recurrent, refractory or progressive NF1-associated pediatric low-grade glioma [39].
\nDrug | \nTarget | \nPhase | \nAge | \nEndpoints | \nStatus | \n
---|---|---|---|---|---|
Vinblastine +/− Bevacizumab NCT02840409 | \nCytotoxic/VEGF | \nII | \n6 months–18 years | \nResponse rate, OS, PFS, visual outcome measures, OCT | \nRecruiting | \n
Pegylated interferon NCT02343224 | \nTumor microenvironment | \nII | \n3–18 years | \nResponse rate | \nRecruiting | \n
Pomalidomide NCT02415153 | \nAngiogenesis/immunomodulation | \nI | \n3–20 years | \nToxicity, MTD | \nActive, not recruiting | \n
Lenalidomide NCT01553149 | \nAngiogenesis/immunomodulation | \nII | \n0–21 years | \nResponse rate | \nActive, not recruiting | \n
Everolimus (RAD0001) NCT01158651 | \nmTOR | \nII | \n1–21 years | \nResponse rate | \nActive, not recruiting | \n
Binimetinib (MEK162) NCT02285439 | \nMEK | \nI/II | \n1–18 years | \nMTD, response rate | \nRecruiting | \n
Binimetinib (MEK162) NCT01885195 | \nMEK | \nII | \nOlder than 18 years | \nResponse rate | \nCompleted (pending results) | \n
Selumetinib NCT01089101 | \nMEK | \nI/II | \n3–21 years | \nSafety, MTD, Response rate | \nRecruiting | \n
Clinical trials for optic pathway gliomas (OPG) and other gliomas associated with neurofibromatosis type 1.
\nAbbreviations: MEK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; VEGF, vascular endothelial growth factor.
Unnecessary cytotoxic therapies for OPG should be avoided, as many OPGs remain asymptomatic and some even regress over time [28]. One of the efforts to standardize the VA assessment in clinical trials for NF1-associated OPG is through using optic coherence tomography (OCT) [40, 41]. OCT provides an objective assessment of the retinal nerve fiber layer thickness. OCT is a noninvasive tool to monitor children with OPG in whom, especially the youngest ones, traditional methods of VA assessment is challenging [42]. Another objective noninvasive tool to asses VA in NF1-associated OPG is automated tractography of the optic radiation that was validated in a recent study [43].
\nA retrospective study that analyzed the clinical and pathological features of gliomas in 100 individuals with NF1 emphasized the wide histologic spectrum of gliomas in those with NF1 [44]. Indeed, individuals with NF1 have an increased risk of malignant gliomas compared with the general population [45], but there are confounding reports on glioblastoma prognosis in those with NF1 vs. cases without NF1 [46, 47]. A recent study analyzed the molecular landscape of gliomas in NF1 and showed that 50% of low-grade gliomas displayed an immune signature, T-lymphocytic infiltrate, and increased neoantigen load [48], findings that may influence future clinical trials in NF1-associated gliomas.
\nMalignant peripheral nerve sheath tumors (MPNSTs) are rare high-grade sarcomas with poor prognosis [49]. MPNSTs occur more frequently in those with NF1 compared with the general population, with a lifetime risk of 8–13% [50]. Several studies have not shown a significant difference in the molecular landscape between sporadic and NF1-associated MPNSTs [51, 52]. FDG-PET remains the gold standard noninvasive diagnostic tool for MPNSTs, with 89–100% sensitivity and 72–95 specificity [53, 54]. Surgical resection with negative margins is the mainstay of treatment [55], though that is not usually feasible. Use of adjuvant radiotherapy to induce local control in MPSNTs failed to show improvement in overall survival in NF1-associated MPNSTs [56].
\nThere are limited chemotherapeutic options, including agents like doxorubicin, and ifosfamide [57, 58]. A phase II study of bevacizumab and everolimus that enrolled 25 individuals (17 had NF1-associated MPNST) did not show a clinical benefit (defined as complete response, partial response or stable disease for ≥4 months) [59]. Although preclinical studies showed EGFR amplification in MPSNT [60], EGFR inhibitors did not show clinical activity against MPNST in clinical trials. A few studies have been conducted in sarcomas using targeted therapy, and these have not shown clinical activity; tested drugs included imatinib [61], dasatinib [62], sorafenib [63], and erlotinib [64]. These negative studies emphasize the importance of developing xenografts to explore new therapeutic targets and explore pathways of interest like the NF1/P53-mutant transgenic MPNST model [65, 66, 67].
\nCombined targeted therapy has been used to exploit cellular vulnerabilities of cancer cells, as in RAS-driven tumors which are refractory to conventional therapies. A preclinical study has shown dramatic tumor shrinkage in a transgenic MPNST mouse model in response to combined HSP90 and mTOR inhibition [68]. This promising preclinical work had led to a phase I/II study of gantespib, a novel injectable inhibitor of HSP90 and the mTOR inhibitor, sirolimus. The study enrolled 20 participants (NCT02008877) and results are pending [69]. Another novel approach undergoing phase I study utilizes the oncolytic potential of the genetically engineered injectable measles virus Edmonston vaccine strain (MVEdm) that encodes thyroid sodium iodide symporter [70] (Table 3).
\nDrug | \nTarget | \nPhase | \nAge (years) | \nEndpoints | \nStatus | \n
---|---|---|---|---|---|
EGFR806 CAR-T cell NCT03618381 | \nImmunotherapy | \nI | \n1–26 | \nToxicity | \nRecruiting | \n
Selumetinib and Sirolimus NCT03433183 | \nMEK and mTOR | \nII | \n≥12 | \nCBR, PFS, OS | \nActive, not recruiting | \n
Injectable MVEdm vaccine strain NCT02700230 | \nOncolytic virotherapy | \nI | \n≥18 | \nToxicity, MTD, ORR | \nRecruiting | \n
Pazopanib vs. Sapanisertib NCT02601209 | \nPDGFR, VEGFR, c-kit (Pazopanib), TORC1&2 (Sapanisertib) | \nI (Sapanisertib), II | \n≥18 | \nMTD, PFS, ORR | \nActive, not recruiting | \n
Lorvotuzumab mertansine NCT02452554 | \nCD-56 antibody | \nII | \n1–30 | \nRECIST | \nActive, not recruiting | \n
Pexidartinib and Sirolimus NCT02584647 | \nc-kit, FLT3, CSF1R, mTOR | \nII | \n≥18 | \nPFS, OS | \nRecruiting | \n
Clinical trials for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
\nAbbreviations: CBR, clinical benefit rate; c-kit, kit ligand or stem cell factor; c-MET, MET proton-oncogene; CSF1R, colony stimulating factor 1 receptor; FLT3, Fms-like tyrosine kinase 11; MEK, mitogen activated protein kinas; MTD, maximum tolerated dose; MVEdm; measles virus edmonston vaccine strain, OS, overall survival; PDGFR platelet-derived growth factor; PFS, progression free survival; RECIST, Response Evaluation Criteria In Solid Tumors; TORC, mammalian target of rapamycin complex; TTP, time to progression; VEGFR vascular endothelial growth factor receptor; ORR, objective response rate.
Cutaneous neurofibromas (cNFs) are among the most common manifestations in NF1, affecting about 99% of patients with NF1 [71]. cNFs are unlikely to undergo malignant transformation or to cause fatal complications or severe neurologic disability. Nevertheless, cNFs are considered one of the greatest concerns in patients, especially adults, with NF1. These concerns are mainly due to disfigurement and dysesthesia, causing substantial psychological distress and negative body image perception [72]. There is immense variability in cNF among patients with NF1 with respect to size, location, age at first presentation, associated symptoms, and number. These factors affect the therapeutic approach to cNFs and emphasize the need for reproducible and reliable endpoints to ensure clinical success for tested agents.
\nClinical management for cNF involves surveillance or procedure-based therapy. Conventional surgical resection promotes complete removal of the lesion, but there are obstacles, including limited number of lesions that can be treated in a single session and the scarring that may be induced by surgical resection. Other alternatives include electrodessication, which remove cNFs through dehydration and denaturation [73]. This allows for removal of large numbers (up to thousands) of cNFs in one session, but it requires general anesthesia and may cause scarring and pigmentation changes. A retrospective study of 106 individuals with multiple, small cNFs treated with CO2 laser ablation reported >90% patient satisfaction, yet a local infection rate was reported to be 15% [74]. Other procedure-based therapies reported in cNFs are laser photocoagulation [75] and radiofrequency ablation [76]. Another approach using local drug/device combinations is the photodynamic therapy (PDT), which is being tested in different cancers [77]. PDT in cNFs studies use a photosensitizer, 5-amino-levulinic acid, plus illumination with red light. PDT was evaluated in phase I study (NCT01682811) and a phase II study (NCT02728388) is active in a single US institution.
\nOne of the early efforts for treatment of cNFs and their associated symptoms used ketotifen [78]. Ketotifen is a histamine 1 receptor blocker which facilitates mast cell stabilization and; its use in NF1 is based on the finding of abundant mast cells in neurofibromas. Improvement in pain and pruritis has been reported, but objective tumor shrinkage has not been documented. Three drugs have been tested in cNFs using local therapeutic approaches; the first was ranibizumab, a vascular endothelial growth factor monoclonal antibody, which was injected intralesionally (NCT00657202). The overall effect of the treatment was minimal and the variability in the tumor volume assessment (measured by a caliper) limited the interpretation of the data. The second agent was topical imiquimod, which showed minimal efficacy in tumor shrinkage compared to baseline volume (measured by a caliper) (NCT00865644). The third agent was topical rapamycin, an mTOR inhibitor, which was initially tested in Tuberous Sclerosis Complex (TSC)-associated angiofibromas (NCT01031901) [79]. The study enrolled 52 patients with TSC and NF1 and data are expected.
\nDue to the relatively benign histology of cNFs and the likely need for long term therapy, there are special considerations pertaining to cNF drug development [80]. The safety profile of tested drugs is a major concern to physicians, regulators, patients and their caregiver. Also, the route of administration and cost are important considerations, as individuals with cNF are more likely to require treatment (either medication or intervention) for an extended period of time. The variant phenotype among affected persons, demographic differences, and the goal of treatment are important factor determining the type and timing of treatment.
\nThe above-mentioned considerations, especially the safety profile, make oral systemic therapies preferable for individuals with a heavy tumor burden. Everolimus, an oral mTOR inhibitor, was evaluated in a phase II study of disfiguring cNF associated with NF1 (NCT02334902). The study enrolled 22 patients and used photographic measurement of selected lesion to assess surface volume. While 5/22 patients withdrew due to adverse events, a very modest effect was reported in <20% of the participants [81]. Due to the promising results of using targeted therapied against MEK, selumetinib is being studied in NF1-associated cNFs (NCT02839720). The study is a phase II, multi-institutional, open label study with the primary outcome measure being the change in the size of cNFs assessed by digital photography and caliper measurements.
\nThe Clinical Trial Design and Development REiNS subgroup, involving experts from different settings, has presented the priorities and challenges associated with conducting clinical trials targeting cNF in NF1 [82]. The subgroup members reviewed key topics like natural history, assessment methods, functional endpoints, safety, and development strategies. One of the most important topics, which pose a major challenge in cNF clinical trials, is the measurement of outcomes. Methods of measurement that have been used include calipers, digital and volume photography, ultrasound, and MRI. The subgroup members support considering clinically meaningful measures of effectiveness in interpreting changes in tumor size or number. Tumor size reduction that correlates with improved pain control or discomfort is more clinically meaningful than the crude number or size of the tumors. New approaches, such as high-frequency ultrasound or optical coherence tomography, may be able to address some of the limitations of the conventional methods like MRI, photography or caliper measurement. These new approaches need to be validated through additional studies. The subgroup members recommend several key factors when designing clinical trials on cNF, including timing to initiate intervention, eligibility criteria to ensure diversity, mechanism of the intervention, route of administration, safety monitoring, and regulatory considerations.
\nNF2 is an autosomal dominant disorder that affects the central and peripheral nervous systems. NF2 has an estimated incidence of 1 in 25,000–33,000 births, making it far less common than NF1 [83]. Vestibular schwannomas (VS) are considered the hallmark of NF2, and bilateral VS fulfill the clinical diagnosis of definite NF2 [84]. The average age at diagnosis in NF2-associated VS is about 27 years [85]; diagnosis in childhood predicts a severe phenotype and unfavorable prognosis [86]. Though VS are slowly progressive tumors, they can cause significant neurologic disability, including hearing loss and eventually deafness, balance problems, and brain stem compression [87]. The other common tumor associated with NF2 is meningioma, which is the most common intracranial tumor worldwide. Up to half of individuals with NF2 develop meningiomas [88], and despite benign histology, they may lead to a shortened life expectancy [89].
\nThe loss of the tumor suppressor protein merlin in NF2 leads to activation of prosurvival pathways via RAS modulation. Hence, NF2 shares many of the same targets identified in NF1. Merlin is absent not only in NF2-associated VS, but also in sporadic VS [90]. This observation is important as it may point to a shared therapeutic pathway between NF2-associated VS and sporadic VS [91].
\nThough surgery remains the mainstay of treatment in sporadic VS, or stereotactic radiosurgery (SRS) for tumors <3 cm [92], these approaches have proved to be less efficacious in NF2-associated VS, with high rate of complications, including facial nerve weakness, hearing loss, and headache [93, 94]. Moreover, there are growing concerns about utilizing radiation therapy in NF2 due to risk of late malignant transformation [95]. Some of the challenges that face NF2 clinical trials are the substantial variability in disease severity across individuals with NF2, the lack of clear association between the rate of VS growth and the rate of hearing loss, and the variable growth rates between the right and the left VS in same patient [96]. A prospective study that highlighted the lack of correlation between VS size or growth rate and rate of hearing loss was published in 2014 and included 120 individuals with NF2-associated VS (total of 200 VS) [97]. The investigators used word recognition score (WRS) as an objective measurement for hearing decline and defined radiographic tumor growth as ≥20% increase in tumor volume compared with baseline. The study showed that the mean rate of hearing decline from diagnosis was 5% at 1 year and 16% at 3 years, while the rate of VS tumor graphic progression was 31% at 1 year and 79% at 3 years. The median time to progression (14 months) was significantly shorter than the median time to hearing decline (62 months) [93]. This study, along with prior reports, elucidated the natural history of individuals with NF2 to help to determine the most appropriate timing for intervention [81, 83, 98].
\nClinical trials for NF2 have been focused on vestibular schwannomas, since loss of hearing is often the most pressing concern in individuals with NF2. A group of 36 international researchers, physicians, representatives from the pharmaceutical industry, and patient advocates held a workshop to provide consensus recommendations to accelerate clinical trials progress in NF2 [99]. The group provided recommendations on participant selection, clinically meaningful and feasible endpoints, the clinical trials models most appropriate for NF2, and candidate therapeutic agents for NF2.
\nDifferent cellular pathways have been targeted in clinical trials for NF2-associated tumors (Table 4), with mixed responses. One of the most promising agents used in NF2 is bevacizumab, which was initially given on a compassionate use basis for adults with NF2-associated VS with severe disability [100, 101]. In these reports, 6 of 10 participants had ≥20% reduction in tumor volume and significantly improved hearing. The promising results led to designing two phase II clinical trials using bevacizumab in persons with NF2 who suffered from progressive hearing loss. A preliminary report from one of these 2 trials that enrolled 22 participants showed that the overall hearing and radiographic response rates were 41 and 23% respectively, though pediatric participants appeared to benefit less compared to adults (NCT01767792) [102]. Bevacizumab was used in a dose of 10 mg/kg every 2 weeks for 6 months, followed by 5 mg/kg every 3 weeks for 18 months; this regimen was well tolerated.
\nDrug | \nTarget | \nPhase | \nAge (years) | \nEndpoints | \nStatus | \n
---|---|---|---|---|---|
Everolimus [104] NCT01419639 | \nmTOR | \nII | \n≥3 | \nVS: 15% volume reductions | \nNo RR | \n
Everolimus [105] NCT01490476 | \nmTOR | \nII | \n≥15 | \nVS: volume reduction | \nNo RR | \n
Everolimus NCT01345136 | \nmTOR | \nII | \n16–65 | \nVS: volume reduction | \nActive, not recruiting | \n
Everolimus NCT01880749 | \nmTOR | \nEarly phase I | \n≥18 | \nVS and MEN: tumor PK, molecular analysis | \nActive, not recruiting | \n
Lapatinib [106] NCT00973739 | \nEGFR/ErBb2 | \nII | \n4–80 | \nVS: 15% volume reduction | \n23.5% RR | \n
Lapatinib NCT00863122 | \nEGFR/ErBb2 | \nEarly phase I | \n≥18 | \nVS: tumor PK, molecular analysis | \nCompleted, pending results | \n
Axitinib NCT02129647 | \nVEGF, c-kit, PDGFR | \nII | \n≥18 | \nVS: 20% volume reduction | \nActive, not recruiting | \n
Nilotinib NCT01201538 | \nPDGF, c-kit | \nII | \n≥18 | \nVS: 20% volume reduction | \nTerminated | \n
PTC 299 NCT00911248 | \nVEGF | \nII | \n≥18 | \nVS: Tumor volume or WRS | \nTerminated | \n
Endostatin NCT02104323 | \nAnti-angiogenic | \nII | \n16–30 | \nTumor volume | \nCompleted, pending results | \n
AR-42 NCT02104323 | \nHDAC | \nEarly phase I | \n≥18 | \nVS and MEN: tumor PK, molecular analysis | \nActive, not recruiting | \n
Bevacizumab [107] NCT01207687 | \nVEGF | \nII | \n≥12 | \nVS: hearing response measured by WRS | \nCompleted, hearing response 36% | \n
Bevacizumab[102] \n NCT01767792 | \nVEGF | \nII | \n≥12 | \nVS: hearing response measured by WRS | \nActive, not recruiting, hearing response 41%, RR 23% | \n
Acetylsalicylic acid NCT03079999 | \nAntiplatelet, anti-inflammatory | \nII, randomized, placebo-control | \n≥12 | \nVS: PFS | \nActive | \n
Vistusertib (AZD2014) NCT02831257 | \nmTORC1, mTORC2 | \nII | \n≥18 | \nMEN: RR using volumetric MRI | \nActive, not recruiting | \n
Selumetinib NCT03095248 | \nMEK | \nII | \n3–45 | \nVS, MEN, and ependymoma: hearing response measured by WRS, RR | \nActive | \n
Clinical trials in Neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.
\nAbbreviations: c-kit, kit ligand or stem cell factor; EGFR/ErBb2, epidermal growth factor reception; HDAC, histone deacetylase; MEK, mitogen activated protein kinas; MEN, meningioma; mTOR, mammalian target of rapamycin; mTORC, mammalian target of rapamycin complex; PDGFR platelet-derived growth factor; PFS, progression-free survival; PK, pharmacokinetics; VEGF, vascular endothelial growth factor; RR, radiographic response; VS. vestibular schwannoma; WRS, word recognition score.
NF2 shares many of the same targets identified in NF1; hence, some of the therapeutic agents tested in NF1 are being tested in NF2, including everolimus (NCT01345136), sorafenib, and selumetinib (NCT03095248). The dual mTROC1 and mTORC2 inhibitor, vistusertib (AZD2014), is used in a phase II study for NF2 patients with progressive or symptomatic meningiomas (NCT02831257). While the primary outcome for this study is the radiographic response rate for meningioma using volumetric MRI scans, the secondary outcomes include response assessment for VS and non-target meningioma using volumetric MRI. The NFCTC has approved using crizotinib, a MET and ALK inhibitor, in a phase II study for children and adults with NF2-associated progressive VS. There are promising preclinical studies identifying crizotinib as a potent inhibitor of NF2-null Schwann cell proliferation in vitro and tumor growth in vivo [103]. The goal for these clinical trials is to assess the hearing response rate as a clinically meaningful endpoint and to assess tolerability and long term effects of the tested agents, as well as identify biomarkers that can predict outcomes.
\nSchwannomatosis (SWN), as the name implies, is characterized by the development of multiple peripheral nerve schwannomas, without concomitant involvement of the vestibular nerve, and, less commonly, meningiomas [108, 109, 110]. Since the schwannoma is the most common tumor in NF2 and SWN, there can be overlap between the two syndromes. SWN is a distinct entity with different clinical phenotype and genetic etiology from NF2. Germline mutations in SMARCB1 and LZTR1, both tumor suppressor genes, have been identified in SWN [111, 112, 113]. Unlike NF1 and NF2, pain is the most common symptom reported by individuals affected with SWN, with 68% reporting chronic pain in SWN in a retrospective study [114].
\nSurgical resection is considered the treatment of choice for symptomatic schwannomas for pain relief, though local recurrence is not uncommon. Patients usually require multiple surgical resections due to pain, focal neurologic deficits, or myelopathy [113]. Radiotherapy is reserved for those with life-threatening or enlarging tumors, and in rare occasions, malignant schwannomas. There are no available safety studies with respect to radiotherapy-induced malignant transformation in SWN, though theoretically it is possible given the available data from NF1, and NF2 studies.
\nUp to date, no clinical trials have been conducted in the setting of SWN and no known effective therapies exist. A case report was published using bevacizumab in one individual with SWN-associated refractory pain with a remarkable response in pain control [115].
\nMost early clinical trials for patients with neurofibromatoses used designs and endpoints similar to oncology trials. However, there are major differences in natural history, disease manifestations, and overall prognosis between patients with NF and those with cancers. Hence, there was an unmet need to establish standardized endpoints in NF clinical trials that will allow precise data interpretation and the ability to assess efficacy across different studies. The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration was established in 2011 at the Children’s Tumor Foundation (CTF) meeting to achieve consensus about the design for future clinical trials with major emphasis on endpoints. The collaboration included 7 working groups; disease biomarkers; whole-body MRI; functional, visual, patient-reported, and neurocognitive outcome; and imaging for tumor response. Later, two more working groups were added; cutaneous neurofibromas, and patient representation [116].
\nThe REiNS Collaboration published the initial recommendations for clinical trials endpoint in 2013 [117]. MRI with volumetric analysis was recommended as the standard imaging metric for pNF and VS in NF1 and NF2 clinical trials [118]. A 20% volume change was chosen to indicate an increase or decrease in the tumor size. MRI analysis requires central review to ensure consistent results. This is a time and resource intensive tool; thus, the development of methods that can be incorporated into routine clinical practice and can be performed more easily is warranted. Whole-body MRI imaging (WB-MRI) may serve as an endpoint in clinical trials that target multiple tumors. The working group concluded that while WB-MRI is feasible for identifying tumors using both 1.5 T and 3.0 T systems, choosing a standardized image acquisition and analysis methods is crucial for applying WB-MRIs as a tool for assessing tumors in NF [119]. For clinical trials targeting NF2-associated VS, the REiNS functional outcomes group endorsed the use of maximum word recognition score as the primary endpoint for hearing. The group recommended using the measurement of improvement in lip excursion (SMILE) system for studies of facial function [120]. For clinical trials targeting NF-associated OPG, the visual outcomes working group recommended the use of visual acuity as the primary endpoint, as opposed to measurement of tumor size [121]. The group also recommended assessing the optic disc for pallor to allow accurate interpretation of the visual acuity. Regarding the neurocognitive outcomes, the working group concluded that The Digit Span (DS) subtest from the Wechsler scales is the most appropriate performance-based outcome measure, as it provides the best psychometrics, feasibility, and utility across a wide age range, and is extensively used in previous research [122]. For similar reasons, the Conners scale achieved the highest ratings of behavioral questionnaires and is considered the most appropriate observe-rated outcome measure.
\nIt is uncommon for pNF to cause airway compromise or pulmonary dysfunction, yet airway pNFs are clinically important. The REiNS functional outcomes group developed consensus recommendations for sleep and pulmonary outcome endpoints in airway pNFs [123]. The group endorsed using the apnea hypopnea index (AHI) as the primary sleep endpoint, and pulmonary resistance at 10 Hz (R10) of forced expiratory volume in 1 or 0.75 seconds (FEV1 or FEV 0.75) as the primary pulmonary endpoint. The group also identified secondary sleep and pulmonary outcomes. Measures of sleep and pulmonary function may be more clinically meaningful as endpoints than changes in tumor size in clinical trials targeting airway pNFs. Regarding patient-reported outcomes (PRO) of pain and physical function in NF clinical trials, the REiNS working group recommended the numeric rating scale-11 (NRS-11) to assess pain intensity for age 8 years and older [124]. To assess pain interference, the group recommended the Pain Interference Index in pediatric studies and the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Interference Scale in adult studies. PROMIS Physical Function Scale was deemed the most appropriate for NF trials to assess the physical functioning domain. The REiNS disease biomarkers working group reported consensus recommendations to provide clinicians and researches with a common set of guidelines to collect and store biospecimens and for establishment of biobanks for neurofibromatoses [125]. The group described the existing biomarkers in NF and report consensus recommendations for standard operation procedures to standardize sample collection and methodology protocols to promote comparison between studies.
\nDrug discovery is a very costly and lengthy process, which may take up to 10 years from first-in-human dosing to approval [126]. This process is usually preceded by years of extensive preclinical research to identify suitable targets for clinical development. The REiNS International Collaboration continues to work on developing consensus endpoints in NF clinical trials and to promote early engagement with FDA and other industry partners to accelerate the drug development and approval for NF-associated tumors.
\nThe field of NF therapeutics is at inflection point. Several clinical trials have been conducted targeting various manifestations of NF and more studies are ongoing. The alignment of endpoints along with utilizing validated clinical outcomes measures represents a priority for therapeutic development for NF. Fortunately, there is a growing interest in NF, which is drawing the attention of pharmaceutical and biotechnology companies to grow the pipeline for NF targeted therapy. These efforts are combined with several ongoing laboratory and preclinical studies that provide unique opportunities to study the complex biology and natural history of NF-associated tumor. The US breakthrough therapy designation that was granted to Selumetinib in NF1 endorses the critical need for partnership among the major consortia and funders to accelerate the therapeutics development efforts in the NF field.
\nMina Lobbous and Bruce Korf report no disclosures relative to the manuscript.
\nIntechOpen implements a robust policy to minimize and deal with instances of fraud or misconduct. As part of our general commitment to transparency and openness, and in order to maintain high scientific standards, we have a well-defined editorial policy regarding Retractions and Corrections.
",metaTitle:"Retraction and Correction Policy",metaDescription:"Retraction and Correction Policy",metaKeywords:null,canonicalURL:"/page/retraction-and-correction-policy",contentRaw:'[{"type":"htmlEditorComponent","content":"IntechOpen’s Retraction and Correction Policy has been developed in accordance with the Committee on Publication Ethics (COPE) publication guidelines relating to scientific misconduct and research ethics:
\\n\\n1. RETRACTIONS
\\n\\nA Retraction of a Chapter will be issued by the Academic Editor, either following an Author’s request to do so or when there is a 3rd party report of scientific misconduct. Upon receipt of a report by a 3rd party, the Academic Editor will investigate any allegations of scientific misconduct, working in cooperation with the Author(s) and their institution(s).
\\n\\nA formal Retraction will be issued when there is clear and conclusive evidence of any of the following:
\\n\\nPublishing of a Retraction Notice will adhere to the following guidelines:
\\n\\n1.2. REMOVALS AND CANCELLATIONS
\\n\\n2. STATEMENTS OF CONCERN
\\n\\nA Statement of Concern detailing alleged misconduct will be issued by the Academic Editor or publisher following a 3rd party report of scientific misconduct when:
\\n\\nIntechOpen believes that the number of occasions on which a Statement of Concern is issued will be very few in number. In all cases when such a decision has been taken by the Academic Editor the decision will be reviewed by another editor to whom the author can make representations.
\\n\\n3. CORRECTIONS
\\n\\nA Correction will be issued by the Academic Editor when:
\\n\\n3.1. ERRATUM
\\n\\nAn Erratum will be issued by the Academic Editor when it is determined that a mistake in a Chapter originates from the production process handled by the publisher.
\\n\\nA published Erratum will adhere to the Retraction Notice publishing guidelines outlined above.
\\n\\n3.2. CORRIGENDUM
\\n\\nA Corrigendum will be issued by the Academic Editor when it is determined that a mistake in a Chapter is a result of an Author’s miscalculation or oversight. A published Corrigendum will adhere to the Retraction Notice publishing guidelines outlined above.
\\n\\n4. FINAL REMARKS
\\n\\nIntechOpen wishes to emphasize that the final decision on whether a Retraction, Statement of Concern, or a Correction will be issued rests with the Academic Editor. The publisher is obliged to act upon any reports of scientific misconduct in its publications and to make a reasonable effort to facilitate any subsequent investigation of such claims.
\\n\\nIn the case of Retraction or removal of the Work, the publisher will be under no obligation to refund the APC.
\\n\\nThe general principles set out above apply to Retractions and Corrections issued in all IntechOpen publications.
\\n\\nAny suggestions or comments on this Policy are welcome and may be sent to permissions@intechopen.com.
\\n\\nPolicy last updated: 2017-09-11
\\n"}]'},components:[{type:"htmlEditorComponent",content:'IntechOpen’s Retraction and Correction Policy has been developed in accordance with the Committee on Publication Ethics (COPE) publication guidelines relating to scientific misconduct and research ethics:
\n\n1. RETRACTIONS
\n\nA Retraction of a Chapter will be issued by the Academic Editor, either following an Author’s request to do so or when there is a 3rd party report of scientific misconduct. Upon receipt of a report by a 3rd party, the Academic Editor will investigate any allegations of scientific misconduct, working in cooperation with the Author(s) and their institution(s).
\n\nA formal Retraction will be issued when there is clear and conclusive evidence of any of the following:
\n\nPublishing of a Retraction Notice will adhere to the following guidelines:
\n\n1.2. REMOVALS AND CANCELLATIONS
\n\n2. STATEMENTS OF CONCERN
\n\nA Statement of Concern detailing alleged misconduct will be issued by the Academic Editor or publisher following a 3rd party report of scientific misconduct when:
\n\nIntechOpen believes that the number of occasions on which a Statement of Concern is issued will be very few in number. In all cases when such a decision has been taken by the Academic Editor the decision will be reviewed by another editor to whom the author can make representations.
\n\n3. CORRECTIONS
\n\nA Correction will be issued by the Academic Editor when:
\n\n3.1. ERRATUM
\n\nAn Erratum will be issued by the Academic Editor when it is determined that a mistake in a Chapter originates from the production process handled by the publisher.
\n\nA published Erratum will adhere to the Retraction Notice publishing guidelines outlined above.
\n\n3.2. CORRIGENDUM
\n\nA Corrigendum will be issued by the Academic Editor when it is determined that a mistake in a Chapter is a result of an Author’s miscalculation or oversight. A published Corrigendum will adhere to the Retraction Notice publishing guidelines outlined above.
\n\n4. FINAL REMARKS
\n\nIntechOpen wishes to emphasize that the final decision on whether a Retraction, Statement of Concern, or a Correction will be issued rests with the Academic Editor. The publisher is obliged to act upon any reports of scientific misconduct in its publications and to make a reasonable effort to facilitate any subsequent investigation of such claims.
\n\nIn the case of Retraction or removal of the Work, the publisher will be under no obligation to refund the APC.
\n\nThe general principles set out above apply to Retractions and Corrections issued in all IntechOpen publications.
\n\nAny suggestions or comments on this Policy are welcome and may be sent to permissions@intechopen.com.
\n\nPolicy last updated: 2017-09-11
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/54719/images/system/54719.jpg",biography:"Prof. Hany A. El-Shemy received his two PhD degrees in Biochemistry and Genetic Engineering from the University of Cairo, Egypt and University of Hiroshima, Japan. He became an assistant professor in the Biochemistry Department of Cairo University, Egypt, from Sept. 1996 and advanced to associate professor in Sept. 2002 as well as a full professor in March 2007. His research interests are in the fields of plant biotechnology and medicinal plants (Molecular Biology). He registered 2 patents, wrote 12 international books, published more than 90 SCI journal papers and 45 conference presentations, and served as the technique committee member as well as chair in many international conferences and the editor in BMC Genomics as well as in Current Issues in Molecular Biology, and also a reviewer for more than 25 SCI cited journals. He received several awards, including State Prize awarded from the Academy of Science, Egypt (2004); Young Arab Researcher Prize awarded from Schuman Foundation, Jordan (2005); State Excellence Prize from the Academy of Science, Egypt (2011 and 2018); and Cairo University Prizes (2007, 2010, and 2014). He served as an expert for African Regional Center for Technology, Dakar, Senegal, plus a visiting professor at Pan African University, African Union, Nairobi, Kenya. He was appointed acting vice president of the Academy of Science and Technology from November 2013 to November 2014, Egypt. He was also a dean of the Faculty of Agriculture, Cairo University from 2014 to 2017.",institutionString:"Cairo University",institution:{name:"Cairo University",country:{name:"Egypt"}}},{id:"93369",title:"Dr.",name:"Yves",middleName:null,surname:"Gibon",slug:"yves-gibon",fullName:"Yves Gibon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Institut National de la Recherche Agronomique",country:{name:"Morocco"}}},{id:"105746",title:"Dr.",name:"A.W.M.M.",middleName:null,surname:"Koopman-van Gemert",slug:"a.w.m.m.-koopman-van-gemert",fullName:"A.W.M.M. Koopman-van Gemert",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/105746/images/5803_n.jpg",biography:"Dr. Anna Wilhelmina Margaretha Maria Koopman-van Gemert MD, PhD, became anaesthesiologist-intensivist from the Radboud University Nijmegen (the Netherlands) in 1987. She worked for a couple of years also as a blood bank director in Nijmegen and introduced in the Netherlands the Cell Saver and blood transfusion alternatives. She performed research in perioperative autotransfusion and obtained the degree of PhD in 1993 publishing Peri-operative autotransfusion by means of a blood cell separator.\nBlood transfusion had her special interest being the president of the Haemovigilance Chamber TRIP and performing several tasks in local and national blood bank and anticoagulant-blood transfusion guidelines committees. Currently, she is working as an associate professor and up till recently was the dean at the Albert Schweitzer Hospital Dordrecht. She performed (inter)national tasks as vice-president of the Concilium Anaesthesia and related committees. \nShe performed research in several fields, with over 100 publications in (inter)national journals and numerous papers on scientific conferences. \nShe received several awards and is a member of Honour of the Dutch Society of Anaesthesia.",institutionString:null,institution:{name:"Albert Schweitzer Hospital",country:{name:"Gabon"}}},{id:"83089",title:"Prof.",name:"Aaron",middleName:null,surname:"Ojule",slug:"aaron-ojule",fullName:"Aaron Ojule",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Port Harcourt",country:{name:"Nigeria"}}},{id:"295748",title:"Mr.",name:"Abayomi",middleName:null,surname:"Modupe",slug:"abayomi-modupe",fullName:"Abayomi Modupe",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/no_image.jpg",biography:null,institutionString:null,institution:{name:"Landmark University",country:{name:"Nigeria"}}},{id:"94191",title:"Prof.",name:"Abbas",middleName:null,surname:"Moustafa",slug:"abbas-moustafa",fullName:"Abbas Moustafa",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/94191/images/96_n.jpg",biography:"Prof. Moustafa got his doctoral degree in earthquake engineering and structural safety from Indian Institute of Science in 2002. He is currently an associate professor at Department of Civil Engineering, Minia University, Egypt and the chairman of Department of Civil Engineering, High Institute of Engineering and Technology, Giza, Egypt. He is also a consultant engineer and head of structural group at Hamza Associates, Giza, Egypt. Dr. Moustafa was a senior research associate at Vanderbilt University and a JSPS fellow at Kyoto and Nagasaki Universities. He has more than 40 research papers published in international journals and conferences. He acts as an editorial board member and a reviewer for several regional and international journals. His research interest includes earthquake engineering, seismic design, nonlinear dynamics, random vibration, structural reliability, structural health monitoring and uncertainty modeling.",institutionString:null,institution:{name:"Minia University",country:{name:"Egypt"}}},{id:"84562",title:"Dr.",name:"Abbyssinia",middleName:null,surname:"Mushunje",slug:"abbyssinia-mushunje",fullName:"Abbyssinia Mushunje",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Fort Hare",country:{name:"South Africa"}}},{id:"202206",title:"Associate Prof.",name:"Abd Elmoniem",middleName:"Ahmed",surname:"Elzain",slug:"abd-elmoniem-elzain",fullName:"Abd Elmoniem Elzain",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Kassala University",country:{name:"Sudan"}}},{id:"98127",title:"Dr.",name:"Abdallah",middleName:null,surname:"Handoura",slug:"abdallah-handoura",fullName:"Abdallah Handoura",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"École Supérieure des Télécommunications",country:{name:"Morocco"}}},{id:"91404",title:"Prof.",name:"Abdecharif",middleName:null,surname:"Boumaza",slug:"abdecharif-boumaza",fullName:"Abdecharif Boumaza",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Abbès Laghrour University of Khenchela",country:{name:"Algeria"}}},{id:"105795",title:"Prof.",name:"Abdel Ghani",middleName:null,surname:"Aissaoui",slug:"abdel-ghani-aissaoui",fullName:"Abdel Ghani Aissaoui",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/105795/images/system/105795.jpeg",biography:"Abdel Ghani AISSAOUI is a Full Professor of electrical engineering at University of Bechar (ALGERIA). He was born in 1969 in Naama, Algeria. He received his BS degree in 1993, the MS degree in 1997, the PhD degree in 2007 from the Electrical Engineering Institute of Djilali Liabes University of Sidi Bel Abbes (ALGERIA). He is an active member of IRECOM (Interaction Réseaux Electriques - COnvertisseurs Machines) Laboratory and IEEE senior member. He is an editor member for many international journals (IJET, RSE, MER, IJECE, etc.), he serves as a reviewer in international journals (IJAC, ECPS, COMPEL, etc.). He serves as member in technical committee (TPC) and reviewer in international conferences (CHUSER 2011, SHUSER 2012, PECON 2012, SAI 2013, SCSE2013, SDM2014, SEB2014, PEMC2014, PEAM2014, SEB (2014, 2015), ICRERA (2015, 2016, 2017, 2018,-2019), etc.). His current research interest includes power electronics, control of electrical machines, artificial intelligence and Renewable energies.",institutionString:"University of Béchar",institution:{name:"University of Béchar",country:{name:"Algeria"}}},{id:"99749",title:"Dr.",name:"Abdel Hafid",middleName:null,surname:"Essadki",slug:"abdel-hafid-essadki",fullName:"Abdel Hafid Essadki",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"École Nationale Supérieure de Technologie",country:{name:"Algeria"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5706},{group:"region",caption:"Middle and South America",value:2,count:5174},{group:"region",caption:"Africa",value:3,count:1690},{group:"region",caption:"Asia",value:4,count:10249},{group:"region",caption:"Australia and Oceania",value:5,count:889},{group:"region",caption:"Europe",value:6,count:15658}],offset:12,limit:12,total:1696},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"dateEndThirdStepPublish"},books:[{type:"book",id:"10547",title:"Physiology and Disorders of Adipose Tissue",subtitle:null,isOpenForSubmission:!0,hash:"b423df09d9aaf08881b015f129af27d0",slug:null,bookSignature:"Dr. Hassan M. Heshmati",coverURL:"https://cdn.intechopen.com/books/images_new/10547.jpg",editedByType:null,editors:[{id:"313921",title:"Dr.",name:"Hassan M.",surname:"Heshmati",slug:"hassan-m.-heshmati",fullName:"Hassan M. Heshmati"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10581",title:"Alkaline Chemistry and Applications",subtitle:null,isOpenForSubmission:!0,hash:"4ed90bdab4a7211c13cd432aa079cd20",slug:null,bookSignature:"Dr. Riadh Marzouki",coverURL:"https://cdn.intechopen.com/books/images_new/10581.jpg",editedByType:null,editors:[{id:"300527",title:"Dr.",name:"Riadh",surname:"Marzouki",slug:"riadh-marzouki",fullName:"Riadh Marzouki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10238",title:"Food Packaging",subtitle:null,isOpenForSubmission:!0,hash:"891ee7ffd87b72cf155fcdf9c8ae5d1a",slug:null,bookSignature:"Dr. Norizah Mhd Sarbon",coverURL:"https://cdn.intechopen.com/books/images_new/10238.jpg",editedByType:null,editors:[{id:"246000",title:"Dr.",name:"Norizah",surname:"Mhd Sarbon",slug:"norizah-mhd-sarbon",fullName:"Norizah Mhd Sarbon"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10374",title:"Advances in Micro- and Nanofluidics",subtitle:null,isOpenForSubmission:!0,hash:"b7ba9cab862a9bca2fc9f9ee72ba5eec",slug:null,bookSignature:"Prof. S. M. Sohel Murshed",coverURL:"https://cdn.intechopen.com/books/images_new/10374.jpg",editedByType:null,editors:[{id:"24904",title:"Prof.",name:"S. M. Sohel",surname:"Murshed",slug:"s.-m.-sohel-murshed",fullName:"S. M. Sohel Murshed"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7724",title:"Climate Issues in Asia and Africa - Examining Climate, Its Flux, the Consequences, and Society's Responses",subtitle:null,isOpenForSubmission:!0,hash:"c1bd1a5a4dba07b95a5ae5ef0ecf9f74",slug:null,bookSignature:" John P. Tiefenbacher",coverURL:"https://cdn.intechopen.com/books/images_new/7724.jpg",editedByType:null,editors:[{id:"73876",title:"Dr.",name:"John P.",surname:"Tiefenbacher",slug:"john-p.-tiefenbacher",fullName:"John P. Tiefenbacher"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10358",title:"Silage - Recent Advances and New Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"1e33f63e9311af352daf51d49f0a3aef",slug:null,bookSignature:"Dr. Juliana Oliveira and Dr. Edson Mauro Santos",coverURL:"https://cdn.intechopen.com/books/images_new/10358.jpg",editedByType:null,editors:[{id:"180036",title:"Dr.",name:"Juliana",surname:"Oliveira",slug:"juliana-oliveira",fullName:"Juliana Oliveira"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9723",title:"Ciliates",subtitle:null,isOpenForSubmission:!0,hash:"7f7a6dc8b1229c1fd5839577497c6a79",slug:null,bookSignature:"Dr. Rosaura Mayén Estrada and Dr. Roberto Junio Pedroso Dias",coverURL:"https://cdn.intechopen.com/books/images_new/9723.jpg",editedByType:null,editors:[{id:"331546",title:"Dr.",name:"Rosaura",surname:"Mayén Estrada",slug:"rosaura-mayen-estrada",fullName:"Rosaura Mayén Estrada"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10471",title:"Advances in Dynamical Systems Theory, Models, Algorithms and Applications",subtitle:null,isOpenForSubmission:!0,hash:"689fdf3cdc78ade03f0c43a245dcf818",slug:null,bookSignature:"Dr. Bruno Carpentieri",coverURL:"https://cdn.intechopen.com/books/images_new/10471.jpg",editedByType:null,editors:[{id:"92921",title:"Dr.",name:"Bruno",surname:"Carpentieri",slug:"bruno-carpentieri",fullName:"Bruno Carpentieri"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10342",title:"Ovarian Cancer - Updates in Tumour Biology and Therapeutics",subtitle:null,isOpenForSubmission:!0,hash:"25a0adac7f6afa7bcd0b6daa3ef6b538",slug:null,bookSignature:"Dr. Gwo Yaw Ho and Dr. Kate Webber",coverURL:"https://cdn.intechopen.com/books/images_new/10342.jpg",editedByType:null,editors:[{id:"297757",title:"Dr.",name:"Gwo Yaw",surname:"Ho",slug:"gwo-yaw-ho",fullName:"Gwo Yaw Ho"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10494",title:"Erythrocyte - a Peripheral Biomarker for Viral and Bacterial Infections",subtitle:null,isOpenForSubmission:!0,hash:"fa5f4b6ef59e28b6e7c1a739c57c5d2f",slug:null,bookSignature:"Prof. Kaneez Fatima Shad",coverURL:"https://cdn.intechopen.com/books/images_new/10494.jpg",editedByType:null,editors:[{id:"31988",title:"Prof.",name:"Kaneez",surname:"Fatima Shad",slug:"kaneez-fatima-shad",fullName:"Kaneez Fatima Shad"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10352",title:"Abdominal Surgery",subtitle:null,isOpenForSubmission:!0,hash:"0d1d92b2286b03cf2fd8d88368d9d9cb",slug:null,bookSignature:"Dr. Ahmad Zaghal and Dr. arwa El Rifai",coverURL:"https://cdn.intechopen.com/books/images_new/10352.jpg",editedByType:null,editors:[{id:"240621",title:"Dr.",name:"Ahmad",surname:"Zaghal",slug:"ahmad-zaghal",fullName:"Ahmad Zaghal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10597",title:"Electric Grid Modernization",subtitle:null,isOpenForSubmission:!0,hash:"62f0e391662f7e8ae35a6bea2e77accf",slug:null,bookSignature:"Dr. Mahmoud Ghofrani",coverURL:"https://cdn.intechopen.com/books/images_new/10597.jpg",editedByType:null,editors:[{id:"183482",title:"Dr.",name:"Mahmoud",surname:"Ghofrani",slug:"mahmoud-ghofrani",fullName:"Mahmoud Ghofrani"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:11},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:14},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:7},{group:"topic",caption:"Computer and Information Science",value:9,count:10},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:4},{group:"topic",caption:"Engineering",value:11,count:16},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:51},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:5},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:148},popularBooks:{featuredBooks:[{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5156},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"6934",title:"Psycho-Social Aspects of Human Sexuality and Ethics",subtitle:null,isOpenForSubmission:!1,hash:"44731b106aa0d1ab5c64a7394483c7d5",slug:"psycho-social-aspects-of-human-sexuality-and-ethics",bookSignature:"Dhastagir Sultan Sheriff",coverURL:"https://cdn.intechopen.com/books/images_new/6934.jpg",editedByType:"Edited by",editors:[{id:"167875",title:"Dr.",name:"Dhastagir Sultan",middleName:null,surname:"Sheriff",slug:"dhastagir-sultan-sheriff",fullName:"Dhastagir Sultan Sheriff"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10062",title:"Forecasting in Mathematics",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"9a3ad05fef0502040d2a238ad22487c0",slug:"forecasting-in-mathematics-recent-advances-new-perspectives-and-applications",bookSignature:"Abdo Abou Jaoude",coverURL:"https://cdn.intechopen.com/books/images_new/10062.jpg",editedByType:"Edited by",editors:[{id:"248271",title:"Dr.",name:"Abdo",middleName:null,surname:"Abou Jaoude",slug:"abdo-abou-jaoude",fullName:"Abdo Abou Jaoude"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9043",title:"Parenting",subtitle:"Studies by an Ecocultural and Transactional Perspective",isOpenForSubmission:!1,hash:"6d21066c7438e459e4c6fb13217a5c8c",slug:"parenting-studies-by-an-ecocultural-and-transactional-perspective",bookSignature:"Loredana Benedetto and Massimo Ingrassia",coverURL:"https://cdn.intechopen.com/books/images_new/9043.jpg",editedByType:"Edited by",editors:[{id:"193200",title:"Prof.",name:"Loredana",middleName:null,surname:"Benedetto",slug:"loredana-benedetto",fullName:"Loredana Benedetto"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10075",title:"Nonlinear Optics",subtitle:"From Solitons to Similaritons",isOpenForSubmission:!1,hash:"b034b2a060292c8511359aec0db1002c",slug:"nonlinear-optics-from-solitons-to-similaritons",bookSignature:"İlkay Bakırtaş and Nalan Antar",coverURL:"https://cdn.intechopen.com/books/images_new/10075.jpg",editedByType:"Edited by",editors:[{id:"186388",title:"Prof.",name:"İlkay",middleName:null,surname:"Bakırtaş",slug:"ilkay-bakirtas",fullName:"İlkay Bakırtaş"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10116",title:"Nano- and Microencapsulation",subtitle:"Techniques and Applications",isOpenForSubmission:!1,hash:"8d92c5999718734b36a0cc3a6af7c7f6",slug:"nano-and-microencapsulation-techniques-and-applications",bookSignature:"Nedal Abu-Thabit",coverURL:"https://cdn.intechopen.com/books/images_new/10116.jpg",editedByType:"Edited by",editors:[{id:"308436",title:"Associate Prof.",name:"Nedal",middleName:null,surname:"Abu-Thabit",slug:"nedal-abu-thabit",fullName:"Nedal Abu-Thabit"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9881",title:"Perovskite and Piezoelectric Materials",subtitle:null,isOpenForSubmission:!1,hash:"8fa0e0f48567bbc50fbb3bfdde6f9a0b",slug:"perovskite-and-piezoelectric-materials",bookSignature:"Someshwar Pola, Neeraj Panwar and Indrani Coondoo",coverURL:"https://cdn.intechopen.com/books/images_new/9881.jpg",editedByType:"Edited by",editors:[{id:"177037",title:"Dr.",name:"Someshwar",middleName:null,surname:"Pola",slug:"someshwar-pola",fullName:"Someshwar Pola"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9394",title:"Genotoxicity and Mutagenicity",subtitle:"Mechanisms and Test Methods",isOpenForSubmission:!1,hash:"9ee7e597358dbbfb5e33d0beb76e6fff",slug:"genotoxicity-and-mutagenicity-mechanisms-and-test-methods",bookSignature:"Sonia Soloneski and Marcelo L. Larramendy",coverURL:"https://cdn.intechopen.com/books/images_new/9394.jpg",editedByType:"Edited by",editors:[{id:"14863",title:"Dr.",name:"Sonia",middleName:null,surname:"Soloneski",slug:"sonia-soloneski",fullName:"Sonia Soloneski"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editedByType:"Edited by",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editedByType:"Edited by",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9569",title:"Methods in Molecular Medicine",subtitle:null,isOpenForSubmission:!1,hash:"691d3f3c4ac25a8093414e9b270d2843",slug:"methods-in-molecular-medicine",bookSignature:"Yusuf Tutar",coverURL:"https://cdn.intechopen.com/books/images_new/9569.jpg",editedByType:"Edited by",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"94",title:"Multimedia",slug:"computer-and-information-science-multimedia",parent:{title:"Computer and Information Science",slug:"computer-and-information-science"},numberOfBooks:8,numberOfAuthorsAndEditors:144,numberOfWosCitations:157,numberOfCrossrefCitations:145,numberOfDimensionsCitations:267,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"computer-and-information-science-multimedia",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"7753",title:"Interactive Multimedia",subtitle:"Multimedia Production and Digital Storytelling",isOpenForSubmission:!1,hash:"ec62348c48f21b53dc2896b6a58f81a5",slug:"interactive-multimedia-multimedia-production-and-digital-storytelling",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/7753.jpg",editedByType:"Edited by",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2214",title:"Virtual Reality in Psychological, Medical and Pedagogical Applications",subtitle:null,isOpenForSubmission:!1,hash:"28049ab50a2bc84b98a9ec96724c143c",slug:"virtual-reality-in-psychological-medical-and-pedagogical-applications",bookSignature:"Christiane Eichenberg",coverURL:"https://cdn.intechopen.com/books/images_new/2214.jpg",editedByType:"Edited by",editors:[{id:"13468",title:"Dr.",name:"Christiane",middleName:null,surname:"Eichenberg",slug:"christiane-eichenberg",fullName:"Christiane Eichenberg"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1950",title:"Video Compression",subtitle:null,isOpenForSubmission:!1,hash:"9db467e8148000cadb877415dc1e4493",slug:"video-compression",bookSignature:"Amal Punchihewa",coverURL:"https://cdn.intechopen.com/books/images_new/1950.jpg",editedByType:"Edited by",editors:[{id:"101553",title:"Dr.",name:"Amal",middleName:null,surname:"Punchihewa",slug:"amal-punchihewa",fullName:"Amal Punchihewa"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2267",title:"Multimedia",subtitle:"A Multidisciplinary Approach to Complex Issues",isOpenForSubmission:!1,hash:"2eb2db2d31c1e4e1acd3a765b433c342",slug:"multimedia-a-multidisciplinary-approach-to-complex-issues",bookSignature:"Ioannis Karydis",coverURL:"https://cdn.intechopen.com/books/images_new/2267.jpg",editedByType:"Edited by",editors:[{id:"118361",title:"Dr.",name:"Ioannis",middleName:null,surname:"Karydis",slug:"ioannis-karydis",fullName:"Ioannis Karydis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1978",title:"Interactive Multimedia",subtitle:null,isOpenForSubmission:!1,hash:"81343be857dbea4b8446359028998656",slug:"interactive-multimedia",bookSignature:"Ioannis Deliyannis",coverURL:"https://cdn.intechopen.com/books/images_new/1978.jpg",editedByType:"Edited by",editors:[{id:"103622",title:"Dr.",name:"Ioannis",middleName:null,surname:"Deliyannis",slug:"ioannis-deliyannis",fullName:"Ioannis Deliyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2268",title:"Advanced Topics in Multimedia Research",subtitle:null,isOpenForSubmission:!1,hash:"dd193b126d9e1444d9c9b2f4e958698a",slug:"advanced-topics-in-multimedia-research",bookSignature:"Sagarmay Deb",coverURL:"https://cdn.intechopen.com/books/images_new/2268.jpg",editedByType:"Edited by",editors:[{id:"120097",title:"Dr.",name:"Sagarmay",middleName:null,surname:"Deb",slug:"sagarmay-deb",fullName:"Sagarmay Deb"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3783",title:"Digital Video",subtitle:null,isOpenForSubmission:!1,hash:"d9d1714aa7ffabceb79c523df32e2b33",slug:"digital-video",bookSignature:"Floriano De Rango",coverURL:"https://cdn.intechopen.com/books/images_new/3783.jpg",editedByType:"Edited by",editors:[{id:"3066",title:"Dr.",name:"Floriano",middleName:null,surname:"De Rango",slug:"floriano-de-rango",fullName:"Floriano De Rango"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5326",title:"Multimedia",subtitle:null,isOpenForSubmission:!1,hash:"54e647d5941a2b75d7be01da16591dab",slug:"multimedia",bookSignature:"Kazuki Nishi",coverURL:"https://cdn.intechopen.com/books/images_new/5326.jpg",editedByType:"Edited by",editors:[{id:"4965",title:"Dr.",name:"Kazuki",middleName:null,surname:"Nishi",slug:"kazuki-nishi",fullName:"Kazuki Nishi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:8,mostCitedChapters:[{id:"39049",doi:"10.5772/50094",title:"Virtual Realities in the Treatment of Mental Disorders: A Review of the Current State of Research",slug:"virtual-realities-in-the-treatment-of-mental-disorders-a-review-of-the-current-state-of-research",totalDownloads:2159,totalCrossrefCites:9,totalDimensionsCites:32,book:{slug:"virtual-reality-in-psychological-medical-and-pedagogical-applications",title:"Virtual Reality in Psychological, Medical and Pedagogical Applications",fullTitle:"Virtual Reality in Psychological, Medical and Pedagogical Applications"},signatures:"Christiane Eichenberg and Carolin Wolters",authors:[{id:"13468",title:"Dr.",name:"Christiane",middleName:null,surname:"Eichenberg",slug:"christiane-eichenberg",fullName:"Christiane Eichenberg"},{id:"159051",title:"B.Sc.",name:"Carolin",middleName:null,surname:"Wolters",slug:"carolin-wolters",fullName:"Carolin Wolters"}]},{id:"31056",doi:"10.5772/37447",title:"Using RFID/NFC and QR-Code in Mobile Phones to Link the Physical and the Digital World",slug:"using-rfid-nfc-and-qr-code-in-mobile-phones-to-link-the-physical-and-the-digital-world",totalDownloads:15830,totalCrossrefCites:21,totalDimensionsCites:30,book:{slug:"interactive-multimedia",title:"Interactive Multimedia",fullTitle:"Interactive Multimedia"},signatures:"Mabel Vazquez-Briseno, Francisco I. Hirata, Juan de Dios Sanchez-Lopez, Elitania Jimenez-Garcia, Christian Navarro-Cota and Juan Ivan Nieto-Hipolito",authors:[{id:"21010",title:"Dr.",name:"Juan De Dios",middleName:null,surname:"Sanchez Lopez",slug:"juan-de-dios-sanchez-lopez",fullName:"Juan De Dios Sanchez Lopez"},{id:"23203",title:"Dr.",name:"Juan Iván",middleName:null,surname:"Nieto Hipólito",slug:"juan-ivan-nieto-hipolito",fullName:"Juan Iván Nieto Hipólito"},{id:"112804",title:"PhD.",name:"Mabel",middleName:null,surname:"Vazquez Briseno",slug:"mabel-vazquez-briseno",fullName:"Mabel Vazquez Briseno"},{id:"136665",title:"Dr.",name:"Francisco Iwao",middleName:null,surname:"Hirata",slug:"francisco-iwao-hirata",fullName:"Francisco Iwao Hirata"},{id:"137172",title:"MSc.",name:"Christian",middleName:null,surname:"Navarro Cota",slug:"christian-navarro-cota",fullName:"Christian Navarro Cota"},{id:"137173",title:"MSc.",name:"Elitania",middleName:null,surname:"Jimenez Garcia",slug:"elitania-jimenez-garcia",fullName:"Elitania Jimenez Garcia"}]},{id:"31064",doi:"10.5772/36036",title:"Multimedia Security: A Survey of Chaos-Based Encryption Technology",slug:"multimedia-security-a-survey-of-chaos-based-encryption-technology",totalDownloads:3970,totalCrossrefCites:12,totalDimensionsCites:20,book:{slug:"multimedia-a-multidisciplinary-approach-to-complex-issues",title:"Multimedia",fullTitle:"Multimedia - A Multidisciplinary Approach to Complex Issues"},signatures:"Zhaopin Su, Guofu Zhang and Jianguo Jiang",authors:[{id:"106867",title:"Dr.",name:"Zhaopin",middleName:null,surname:"Su",slug:"zhaopin-su",fullName:"Zhaopin Su"},{id:"106875",title:"Dr.",name:"Guofu",middleName:null,surname:"Zhang",slug:"guofu-zhang",fullName:"Guofu Zhang"},{id:"106877",title:"Prof.",name:"Jianguo",middleName:null,surname:"Jiang",slug:"jianguo-jiang",fullName:"Jianguo Jiang"}]}],mostDownloadedChaptersLast30Days:[{id:"8531",title:"Building Principles and Application of Multifunctional Video Information System",slug:"building-principles-and-application-of-multifunctional-video-information-system",totalDownloads:1773,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"digital-video",title:"Digital Video",fullTitle:"Digital Video"},signatures:"Mahmudov Ergash B. and Fedosov Andrew A.",authors:null},{id:"31069",title:"Mconf: An Open Source Multiconference System for Web and Mobile Devices",slug:"mconf-an-open-source-multiconference-system-for-web-and-mobile-devices",totalDownloads:7020,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"multimedia-a-multidisciplinary-approach-to-complex-issues",title:"Multimedia",fullTitle:"Multimedia - A Multidisciplinary Approach to Complex Issues"},signatures:"Valter Roesler, Felipe Cecagno, Leonardo Crauss Daronco and Fred Dixon",authors:[{id:"38761",title:"Mr.",name:"Valter",middleName:null,surname:"Roesler",slug:"valter-roesler",fullName:"Valter Roesler"},{id:"111923",title:"MSc.",name:"Leonardo Crauss",middleName:null,surname:"Daronco",slug:"leonardo-crauss-daronco",fullName:"Leonardo Crauss Daronco"},{id:"111924",title:"BSc.",name:"Felipe",middleName:null,surname:"Cecagno",slug:"felipe-cecagno",fullName:"Felipe Cecagno"},{id:"137182",title:"Mr.",name:"Fred",middleName:null,surname:"Dixon",slug:"fred-dixon",fullName:"Fred Dixon"}]},{id:"39043",title:"Virtual Reality – A New Era in Surgical Training",slug:"virtual-reality-a-new-era-in-surgical-training",totalDownloads:2051,totalCrossrefCites:10,totalDimensionsCites:13,book:{slug:"virtual-reality-in-psychological-medical-and-pedagogical-applications",title:"Virtual Reality in Psychological, Medical and Pedagogical Applications",fullTitle:"Virtual Reality in Psychological, Medical and Pedagogical Applications"},signatures:"C.E. Buckley, E. Nugent, D. Ryan and P.C. Neary",authors:[{id:"37650",title:"Prof.",name:"Paul",middleName:null,surname:"Neary",slug:"paul-neary",fullName:"Paul Neary"},{id:"42530",title:"Dr.",name:"Emmeline",middleName:null,surname:"Nugent",slug:"emmeline-nugent",fullName:"Emmeline Nugent"},{id:"146973",title:"Dr.",name:"Christina",middleName:null,surname:"Buckley",slug:"christina-buckley",fullName:"Christina Buckley"},{id:"153270",title:"Mr.",name:"Donncha",middleName:null,surname:"Ryan",slug:"donncha-ryan",fullName:"Donncha Ryan"}]},{id:"31045",title:"From Interactive to Experimental Multimedia",slug:"from-interactive-multimedia-to-experimental-multimedia",totalDownloads:3048,totalCrossrefCites:4,totalDimensionsCites:4,book:{slug:"interactive-multimedia",title:"Interactive Multimedia",fullTitle:"Interactive Multimedia"},signatures:"Ioannis Deliyannis",authors:[{id:"103622",title:"Dr.",name:"Ioannis",middleName:null,surname:"Deliyannis",slug:"ioannis-deliyannis",fullName:"Ioannis Deliyannis"}]},{id:"8510",title:"Multimedia Traffic over Wireless and Satellite Networks",slug:"multimedia-traffic-over-wireless-and-satellite-networks",totalDownloads:3680,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"digital-video",title:"Digital Video",fullTitle:"Digital Video"},signatures:"Floriano De Rango, Mauro Tropea and Peppino Fazio",authors:null},{id:"39042",title:"Being There: Understanding the Feeling of Presence in a Synthetic Environment and its Potential for Clinical Change",slug:"being-there-understanding-the-feeling-of-presence-in-a-synthetic-environment-and-its-potential-for-c",totalDownloads:1838,totalCrossrefCites:7,totalDimensionsCites:9,book:{slug:"virtual-reality-in-psychological-medical-and-pedagogical-applications",title:"Virtual Reality in Psychological, Medical and Pedagogical Applications",fullTitle:"Virtual Reality in Psychological, Medical and Pedagogical Applications"},signatures:"Giuseppe Riva and Fabrizia Mantovani",authors:[{id:"149802",title:"Prof.",name:"Giuseppe",middleName:null,surname:"Riva",slug:"giuseppe-riva",fullName:"Giuseppe Riva"},{id:"149803",title:"Prof.",name:"Fabrizia",middleName:null,surname:"Mantovani",slug:"fabrizia-mantovani",fullName:"Fabrizia Mantovani"}]},{id:"64010",title:"Transactional Distance Theory: A Critical View of the Theoretical and Pedagogical Underpinnings of E-Learning",slug:"transactional-distance-theory-a-critical-view-of-the-theoretical-and-pedagogical-underpinnings-of-e-",totalDownloads:735,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"interactive-multimedia-multimedia-production-and-digital-storytelling",title:"Interactive Multimedia",fullTitle:"Interactive Multimedia - Multimedia Production and Digital Storytelling"},signatures:"Laura Delgaty",authors:null},{id:"31055",title:"Building Adaptive Rich Interfaces for Interactive Ubiquitous Applications",slug:"building-adaptive-rich-interfaces-for-interactive-ubiquitous-applications",totalDownloads:2357,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"interactive-multimedia",title:"Interactive Multimedia",fullTitle:"Interactive Multimedia"},signatures:"Carlos Eduardo Cirilo, Antonio Francisco do Prado, Wanderley Lopes de Souza and Luciana Aparecida Martinez Zaina",authors:[{id:"22586",title:"Prof.",name:"Wanderley",middleName:null,surname:"Lopes de Souza",slug:"wanderley-lopes-de-souza",fullName:"Wanderley Lopes de Souza"},{id:"25557",title:"Prof.",name:"Antonio Francisco",middleName:null,surname:"Do Prado",slug:"antonio-francisco-do-prado",fullName:"Antonio Francisco Do Prado"},{id:"103987",title:"MSc.",name:"Carlos Eduardo",middleName:null,surname:"Cirilo",slug:"carlos-eduardo-cirilo",fullName:"Carlos Eduardo Cirilo"},{id:"113827",title:"Prof.",name:"Luciana Aparecida Martinez",middleName:null,surname:"Zaina",slug:"luciana-aparecida-martinez-zaina",fullName:"Luciana Aparecida Martinez Zaina"}]},{id:"39041",title:"Virtual Reality and Body Dissatisfaction Across the Eating Disorder’s Spectrum",slug:"virtual-reality-and-body-dissatisfaction-across-the-eating-disorder-s-spectrum",totalDownloads:1595,totalCrossrefCites:3,totalDimensionsCites:5,book:{slug:"virtual-reality-in-psychological-medical-and-pedagogical-applications",title:"Virtual Reality in Psychological, Medical and Pedagogical Applications",fullTitle:"Virtual Reality in Psychological, Medical and Pedagogical Applications"},signatures:"Annie Aimé, Karine Cotton, Tanya Guitard and Stéphane Bouchard",authors:[{id:"13561",title:"Dr.",name:"Stephane",middleName:".",surname:"Bouchard",slug:"stephane-bouchard",fullName:"Stephane Bouchard"},{id:"140031",title:"MSc.",name:"Tanya",middleName:null,surname:"Guitard",slug:"tanya-guitard",fullName:"Tanya Guitard"},{id:"146020",title:"Prof.",name:"Annie",middleName:null,surname:"Aime",slug:"annie-aime",fullName:"Annie Aime"},{id:"149018",title:"BSc.",name:"Karine",middleName:null,surname:"Cotton",slug:"karine-cotton",fullName:"Karine Cotton"}]},{id:"31059",title:"Real-Time Multimedia Stream Data Processing in a Supercomputer Environment",slug:"real-time-multimedia-stream-data-processing-in-a-supercomputer-environment",totalDownloads:1958,totalCrossrefCites:6,totalDimensionsCites:5,book:{slug:"interactive-multimedia",title:"Interactive Multimedia",fullTitle:"Interactive Multimedia"},signatures:"Henryk Krawczyk and Jerzy Proficz",authors:[{id:"109320",title:"Prof.",name:"Henryk",middleName:null,surname:"Krawczyk",slug:"henryk-krawczyk",fullName:"Henryk Krawczyk"},{id:"114035",title:"MSc.",name:"Jerzy",middleName:null,surname:"Proficz",slug:"jerzy-proficz",fullName:"Jerzy Proficz"}]}],onlineFirstChaptersFilter:{topicSlug:"computer-and-information-science-multimedia",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/143304/zbigniew-j.-kaminski",hash:"",query:{},params:{id:"143304",slug:"zbigniew-j.-kaminski"},fullPath:"/profiles/143304/zbigniew-j.-kaminski",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()